0000095953December 312026Q2falseP3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureacnt:segment00000959532026-01-012026-06-3000000959532026-07-3100000959532026-06-3000000959532025-12-3100000959532025-01-012025-12-3100000959532026-04-012026-06-3000000959532025-04-012025-06-3000000959532025-01-012025-06-3000000959532024-12-3100000959532025-06-300000095953us-gaap:CommonStockMember2026-03-310000095953us-gaap:AdditionalPaidInCapitalMember2026-03-310000095953us-gaap:RetainedEarningsMember2026-03-310000095953us-gaap:TreasuryStockCommonMember2026-03-3100000959532026-03-310000095953us-gaap:RetainedEarningsMember2026-04-012026-06-300000095953us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300000095953us-gaap:TreasuryStockCommonMember2026-04-012026-06-300000095953us-gaap:CommonStockMember2026-06-300000095953us-gaap:AdditionalPaidInCapitalMember2026-06-300000095953us-gaap:RetainedEarningsMember2026-06-300000095953us-gaap:TreasuryStockCommonMember2026-06-300000095953us-gaap:CommonStockMember2025-12-310000095953us-gaap:AdditionalPaidInCapitalMember2025-12-310000095953us-gaap:RetainedEarningsMember2025-12-310000095953us-gaap:TreasuryStockCommonMember2025-12-310000095953us-gaap:RetainedEarningsMember2026-01-012026-06-300000095953us-gaap:AdditionalPaidInCapitalMember2026-01-012026-06-300000095953us-gaap:TreasuryStockCommonMember2026-01-012026-06-300000095953us-gaap:CommonStockMember2025-03-310000095953us-gaap:AdditionalPaidInCapitalMember2025-03-310000095953us-gaap:RetainedEarningsMember2025-03-310000095953us-gaap:TreasuryStockCommonMember2025-03-3100000959532025-03-310000095953us-gaap:RetainedEarningsMember2025-04-012025-06-300000095953us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300000095953us-gaap:TreasuryStockCommonMember2025-04-012025-06-300000095953us-gaap:CommonStockMember2025-06-300000095953us-gaap:AdditionalPaidInCapitalMember2025-06-300000095953us-gaap:RetainedEarningsMember2025-06-300000095953us-gaap:TreasuryStockCommonMember2025-06-300000095953us-gaap:CommonStockMember2024-12-310000095953us-gaap:AdditionalPaidInCapitalMember2024-12-310000095953us-gaap:RetainedEarningsMember2024-12-310000095953us-gaap:TreasuryStockCommonMember2024-12-310000095953us-gaap:RetainedEarningsMember2025-01-012025-06-300000095953us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300000095953us-gaap:TreasuryStockCommonMember2025-01-012025-06-300000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-05-040000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-05-042026-05-040000095953acnt:SpecialtyChemicalsSegmentMemberacnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-05-040000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Memberus-gaap:TrademarksAndTradeNamesMember2026-05-040000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Memberus-gaap:CustomerRelationshipsMember2026-05-040000095953srt:MinimumMemberacnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-05-040000095953srt:MaximumMemberacnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-05-040000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-05-042026-06-300000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Memberacnt:IntangibleAssetAmortizationMember2026-05-042026-06-300000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-04-012026-06-300000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2025-04-012025-06-300000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2026-01-012026-06-300000095953acnt:MidwestGraphicSalesInc.AndSigmaCoatingsInc.Member2025-01-012025-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMemberacnt:BristolMetalsLLCMember2025-03-122025-03-120000095953us-gaap:DiscontinuedOperationsHeldforsaleMemberacnt:BristolMetalsLLCMember2025-03-120000095953us-gaap:DiscontinuedOperationsHeldforsaleMemberacnt:AmericanStainlessTubingLLCMember2025-06-302025-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMemberacnt:AmericanStainlessTubingLLCMember2025-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMember2026-04-012026-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMember2025-04-012025-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMember2026-01-012026-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMember2025-01-012025-06-300000095953acnt:CustomManufacturingMember2026-04-012026-06-300000095953acnt:CustomManufacturingMember2025-04-012025-06-300000095953acnt:CustomManufacturingMember2026-01-012026-06-300000095953acnt:CustomManufacturingMember2025-01-012025-06-300000095953acnt:CoreTechnologyMember2026-04-012026-06-300000095953acnt:CoreTechnologyMember2025-04-012025-06-300000095953acnt:CoreTechnologyMember2026-01-012026-06-300000095953acnt:CoreTechnologyMember2025-01-012025-06-300000095953acnt:DistributionMember2026-04-012026-06-300000095953acnt:DistributionMember2025-04-012025-06-300000095953acnt:DistributionMember2026-01-012026-06-300000095953acnt:DistributionMember2025-01-012025-06-300000095953us-gaap:TransferredAtPointInTimeMember2026-04-012026-06-300000095953us-gaap:TransferredAtPointInTimeMember2025-04-012025-06-300000095953us-gaap:TransferredAtPointInTimeMember2026-01-012026-06-300000095953us-gaap:TransferredAtPointInTimeMember2025-01-012025-06-300000095953us-gaap:TransferredOverTimeMember2026-04-012026-06-300000095953us-gaap:TransferredOverTimeMember2025-04-012025-06-300000095953us-gaap:TransferredOverTimeMember2026-01-012026-06-300000095953us-gaap:TransferredOverTimeMember2025-01-012025-06-300000095953us-gaap:DiscontinuedOperationsHeldforsaleMemberacnt:MunhallFacilityMember2025-04-012025-06-300000095953us-gaap:LandMember2026-06-300000095953us-gaap:LandMember2025-12-310000095953us-gaap:LandImprovementsMember2026-06-300000095953us-gaap:LandImprovementsMember2025-12-310000095953us-gaap:BuildingMember2026-06-300000095953us-gaap:BuildingMember2025-12-310000095953us-gaap:MachineryAndEquipmentMember2026-06-300000095953us-gaap:MachineryAndEquipmentMember2025-12-310000095953us-gaap:ConstructionInProgressMember2026-06-300000095953us-gaap:ConstructionInProgressMember2025-12-310000095953us-gaap:CostOfGoodsAndServicesSold2026-04-012026-06-300000095953us-gaap:CostOfGoodsAndServicesSold2025-04-012025-06-300000095953us-gaap:CostOfGoodsAndServicesSold2026-01-012026-06-300000095953us-gaap:CostOfGoodsAndServicesSold2025-01-012025-06-300000095953acnt:SellingGeneralAndAdministrativeExpenseAndDepreciationDepletionAndAmortization2026-04-012026-06-300000095953acnt:SellingGeneralAndAdministrativeExpenseAndDepreciationDepletionAndAmortization2025-04-012025-06-300000095953acnt:SellingGeneralAndAdministrativeExpenseAndDepreciationDepletionAndAmortization2026-01-012026-06-300000095953acnt:SellingGeneralAndAdministrativeExpenseAndDepreciationDepletionAndAmortization2025-01-012025-06-300000095953srt:MinimumMember2026-06-300000095953srt:MaximumMember2026-06-300000095953us-gaap:CustomerRelationshipsMember2026-01-012026-06-300000095953us-gaap:CustomerRelatedIntangibleAssetsMember2026-06-300000095953us-gaap:CustomerRelatedIntangibleAssetsMember2025-12-310000095953us-gaap:TrademarksAndTradeNamesMember2026-06-300000095953us-gaap:TrademarksAndTradeNamesMember2025-12-310000095953us-gaap:OtherIntangibleAssetsMember2026-06-300000095953us-gaap:OtherIntangibleAssetsMember2025-12-310000095953us-gaap:NotesPayableToBanksMember2026-05-290000095953us-gaap:LineOfCreditMemberacnt:TheFacilityMemberus-gaap:RevolvingCreditFacilityMember2025-12-100000095953acnt:TheFacilityMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2025-12-102025-12-100000095953acnt:TheFacilityMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2025-12-102025-12-100000095953us-gaap:LineOfCreditMemberacnt:TheFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2026-01-012026-06-300000095953us-gaap:LineOfCreditMemberacnt:TheFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2026-01-012026-06-300000095953us-gaap:RevolvingCreditFacilityMember2026-06-300000095953us-gaap:RevolvingCreditFacilityMember2025-12-310000095953us-gaap:LineOfCreditMemberacnt:ABLLineOfCreditDueJanuary152025Memberus-gaap:RevolvingCreditFacilityMember2026-06-300000095953acnt:FifthAmendedAndRestatedMasterLeaseAgreementMember2025-04-042025-04-0400000959532025-04-042025-04-040000095953acnt:SixthAmendedAndRestatedMasterLeaseAgreementMember2025-06-302025-06-300000095953acnt:SeventhAmendedAndRestatedMasterLeaseAgreementMember2025-10-012025-12-3100000959532025-12-1900000959532025-12-192025-12-190000095953acnt:AmendedShareRepurchaseProgramMember2026-06-300000095953us-gaap:OperatingSegmentsMemberacnt:SpecialtyChemicalsSegmentMember2026-04-012026-06-300000095953us-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953us-gaap:OperatingSegmentsMemberacnt:SpecialtyChemicalsSegmentMember2026-01-012026-06-300000095953us-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953country:USacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000095953country:USus-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953country:US2026-04-012026-06-300000095953country:USacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000095953country:USus-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953country:US2026-01-012026-06-300000095953country:HNacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000095953country:HNus-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953country:HN2026-04-012026-06-300000095953country:HNacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000095953country:HNus-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953country:HN2026-01-012026-06-300000095953country:MXacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000095953country:MXus-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953country:MX2026-04-012026-06-300000095953country:MXacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000095953country:MXus-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953country:MX2026-01-012026-06-300000095953country:CAacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000095953country:CAus-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953country:CA2026-04-012026-06-300000095953country:CAacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000095953country:CAus-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953country:CA2026-01-012026-06-300000095953country:COacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000095953country:COus-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953country:CO2026-04-012026-06-300000095953country:COacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000095953country:COus-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953country:CO2026-01-012026-06-300000095953acnt:AllOtherCountriesMemberacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000095953acnt:AllOtherCountriesMemberus-gaap:CorporateNonSegmentMember2026-04-012026-06-300000095953acnt:AllOtherCountriesMember2026-04-012026-06-300000095953acnt:AllOtherCountriesMemberacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000095953acnt:AllOtherCountriesMemberus-gaap:CorporateNonSegmentMember2026-01-012026-06-300000095953acnt:AllOtherCountriesMember2026-01-012026-06-300000095953us-gaap:OperatingSegmentsMemberacnt:SpecialtyChemicalsSegmentMember2025-04-012025-06-300000095953us-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953us-gaap:OperatingSegmentsMemberacnt:SpecialtyChemicalsSegmentMember2025-01-012025-06-300000095953us-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:USacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:USus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:US2025-04-012025-06-300000095953country:USacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:USus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:US2025-01-012025-06-300000095953country:MXacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:MXus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:MX2025-04-012025-06-300000095953country:MXacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:MXus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:MX2025-01-012025-06-300000095953country:CAacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:CAus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:CA2025-04-012025-06-300000095953country:CAacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:CAus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:CA2025-01-012025-06-300000095953country:COacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:COus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:CO2025-04-012025-06-300000095953country:COacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:COus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:CO2025-01-012025-06-300000095953country:NLacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:NLus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:NL2025-04-012025-06-300000095953country:NLacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:NLus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:NL2025-01-012025-06-300000095953country:HNacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:HNus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:HN2025-04-012025-06-300000095953country:HNacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:HNus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:HN2025-01-012025-06-300000095953country:CRacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953country:CRus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953country:CR2025-04-012025-06-300000095953country:CRacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953country:CRus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953country:CR2025-01-012025-06-300000095953acnt:AllOtherCountriesMemberacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000095953acnt:AllOtherCountriesMemberus-gaap:CorporateNonSegmentMember2025-04-012025-06-300000095953acnt:AllOtherCountriesMember2025-04-012025-06-300000095953acnt:AllOtherCountriesMemberacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000095953acnt:AllOtherCountriesMemberus-gaap:CorporateNonSegmentMember2025-01-012025-06-300000095953acnt:AllOtherCountriesMember2025-01-012025-06-300000095953us-gaap:SegmentContinuingOperationsMemberacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2026-06-300000095953us-gaap:SegmentContinuingOperationsMemberacnt:SpecialtyChemicalsSegmentMemberus-gaap:OperatingSegmentsMember2025-12-310000095953us-gaap:SegmentContinuingOperationsMemberus-gaap:CorporateNonSegmentMember2026-06-300000095953us-gaap:SegmentContinuingOperationsMemberus-gaap:CorporateNonSegmentMember2025-12-310000095953us-gaap:SegmentContinuingOperationsMember2026-06-300000095953us-gaap:SegmentContinuingOperationsMember2025-12-3100000959532026-05-042026-05-040000095953us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberacnt:TheFacilityMemberus-gaap:RevolvingCreditFacilityMember2026-07-170000095953us-gaap:SubsequentEventMemberacnt:TheFacilityMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2026-07-172026-07-170000095953us-gaap:SubsequentEventMemberacnt:TheFacilityMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2026-07-172026-07-170000095953us-gaap:SubsequentEventMember2026-07-012026-07-31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| | | | | | | | |
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2026
OR
| | | | | |
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the Transition Period from _____ to _____ |
COMMISSION FILE NUMBER 0-19687
Ascent Industries Co.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
| Delaware | | | 57-0426694 |
| (State or other jurisdiction of incorporation or organization) | | | (I.R.S. Employer Identification No.) |
| | | | |
| 20 N. Martingale Rd, | Suite 430, | | | |
| Schaumburg, | Illinois | | | 60173 |
| (Address of principal executive offices) | | | (Zip Code) |
| | (630) | 884-9181 | |
| | (Registrant's telephone number, including area code) | |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol | Name of exchange on which registered |
| Common Stock, par value $1.00 per share | ACNT | NASDAQ Global Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | |
| Large accelerated filer | ☐ | Accelerated filer | x | Non-accelerated filer | ☐ |
| Smaller reporting company | x | Emerging growth company | ☐ | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No x
The number of shares outstanding of the registrant's common stock as of July 31, 2026 was 9,009,453
Ascent Industries Co.
Table of Contents
| | | | | | | | | | | |
| | | |
| PART I. FINANCIAL INFORMATION |
| |
Item 1. | | Financial Statements | |
| | | |
| | | |
| | | |
| | | |
| | Notes to Condensed Consolidated Financial Statements (unaudited) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Item 2. | | | |
| Item 3. | | | |
| Item 4. | | | |
| | | |
| PART II. OTHER INFORMATION |
| Item 1. | | | |
Item 1A. | | | |
| Item 2. | | | |
| Item 3. | | | |
| Item 4. | | | |
| Item 5. | | | |
| Item 6. | | | |
| | | |
| | | |
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties, including without limitation those identified below, which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. The following factors could cause actual results to differ materially from historical results or those anticipated: adverse economic conditions, including risks relating to the impact and spread of and the government’s response to pandemics; inability to weather an economic downturn; the impact of competitive products and pricing; product demand and acceptance risks; raw material and other increased costs, including the impact of tariffs; raw material availability; financial stability of the Company’s customers; customer delays or difficulties in the production of products; loss of consumer or investor confidence; employee relations; ability to maintain workforce by hiring trained employees; labor efficiencies; risks associated with acquisitions; environmental issues; negative or unexpected results from tax law changes; inability to comply with covenants and ratios required by the Company’s debt financing arrangements; and other risks detailed from time-to-time in Ascent Industries Co.'s Securities and Exchange Commission filings, including our Annual Report on Form 10-K, which filings are available from the SEC. Ascent Industries Co. assumes no obligation to update any forward-looking information included in this release.
Part I - Financial Information
Item 1. Financial Statements
Ascent Industries Co.
Condensed Consolidated Balance Sheets
(in thousands, except par value and share data)
| | | | | | | | | | | |
| (Unaudited) | | |
| June 30, 2026 | | December 31, 2025 |
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 28,069 | | | $ | 57,606 | |
Accounts receivable, net of allowance for credit losses of $119 and $1,004, respectively | 18,642 | | | 10,040 | |
| Advances and other receivables | 5,406 | | | 5,389 | |
| Inventories | 10,488 | | | 8,742 | |
| Prepaid expenses and other current assets | 2,115 | | | 1,243 | |
| | | |
| | | |
| Total current assets | 64,720 | | | 83,020 | |
| Property, plant and equipment, net | 15,693 | | | 15,762 | |
| Right-of-use assets, operating leases, net | 9,074 | | | 9,368 | |
| Goodwill | 4,735 | | | — | |
| Intangible assets, net | 10,008 | | | 2,833 | |
| Deferred income taxes | 279 | | | — | |
| Deferred charges, net | 301 | | | 401 | |
| Other non-current assets, net | 1,506 | | | 553 | |
| | | |
| Total assets | $ | 106,316 | | | $ | 111,937 | |
| | | |
| Liabilities and Shareholders' Equity | | | |
| Current liabilities: | | | |
| Accounts payable | $ | 9,125 | | | $ | 5,490 | |
| | | |
| Accrued expenses and other current liabilities | 3,689 | | | 5,389 | |
| Current portion of note payable | 997 | | | 433 | |
| Deferred revenue | 34 | | | — | |
| | | |
| | | |
| Current portion of operating lease liabilities | 754 | | | 712 | |
| Current portion of finance lease liabilities | 340 | | | 331 | |
| | | |
| Total current liabilities | 14,939 | | | 12,355 | |
| | | |
| | | |
| Long-term portion of operating lease liabilities | 11,105 | | | 11,496 | |
| Long-term portion of finance lease liabilities | 635 | | | 808 | |
| Deferred income taxes | — | | | 241 | |
| Other long-term liabilities | 41 | | | 45 | |
| | | |
| Total non-current liabilities | 11,781 | | | 12,590 | |
| Total liabilities | $ | 26,720 | | | $ | 24,945 | |
| | | |
| Commitments and contingencies – See Note 14 | | | |
| | | |
| Shareholders' equity: | | | |
Common stock, par value $1 per share; 24,000,000 shares authorized; 9,009,453 and 9,400,898 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | $ | 11,085 | | | $ | 11,085 | |
| Capital in excess of par value | 47,791 | | | 48,276 | |
| Retained earnings | 44,476 | | | 45,786 | |
| 103,352 | | | 105,147 | |
Less: cost of common stock in treasury - 2,075,650 and 1,684,205 shares, respectively | (23,756) | | | (18,155) | |
| Total shareholders' equity | 79,596 | | | 86,992 | |
| Total liabilities and shareholders' equity | $ | 106,316 | | | $ | 111,937 | |
Note: The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date. See accompanying notes to condensed consolidated financial statements.
Ascent Industries Co.
Condensed Consolidated Statements of Income (Loss) (Unaudited)
(in thousands, except per share data)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2026 | | 2025 | | 2026 | | 2025 |
| Net sales | $ | 25,667 | | | $ | 18,652 | | | $ | 45,083 | | | $ | 36,486 | |
| Cost of sales | 20,119 | | | 13,786 | | | 36,723 | | | 28,553 | |
| Gross profit | 5,548 | | | 4,866 | | | 8,360 | | | 7,933 | |
| Selling, general and administrative | 5,527 | | | 6,444 | | | 10,650 | | | 11,315 | |
| Research and development | 107 | | | — | | | 170 | | | — | |
| Acquisition costs and other | 176 | | | 31 | | | 177 | | | 268 | |
| | | | | | | |
| Asset impairments | — | | | 1,622 | | | — | | | 1,622 | |
| | | | | | | |
| | | | | | | |
| Gain on lease modification | — | | | (544) | | | — | | | (544) | |
| Operating loss from continuing operations | (262) | | | (2,687) | | | (2,637) | | | (4,728) | |
| Other expense (income) | | | | | | | |
| Interest expense (income), net | (155) | | | (15) | | | (448) | | | 99 | |
| | | | | | | |
| | | | | | | |
| Other, net | (176) | | | (136) | | | (392) | | | (285) | |
| Income (loss) from continuing operations before income taxes | 69 | | | (2,536) | | | (1,797) | | | (4,542) | |
| Income tax benefit | (601) | | | (89) | | | (487) | | | (89) | |
| Income (loss) from continuing operations | 670 | | | (2,447) | | | (1,310) | | | (4,453) | |
| Income from discontinued operations, net of tax | — | | | 8,733 | | | — | | | 8,446 | |
| Net income (loss) | $ | 670 | | | $ | 6,286 | | | $ | (1,310) | | | $ | 3,993 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Net income (loss) per common share from continuing operations: | | | | | | | |
| Basic | $ | 0.07 | | | $ | (0.25) | | | $ | (0.14) | | | $ | (0.45) | |
| Diluted | $ | 0.07 | | | $ | (0.25) | | | $ | (0.14) | | | $ | (0.45) | |
| | | | | | | |
| Net income per common share from discontinued operations: | | | | | | | |
| Basic | $ | — | | | $ | 0.90 | | | $ | — | | | $ | 0.85 | |
| Diluted | $ | — | | | $ | 0.90 | | | $ | — | | | $ | 0.85 | |
| | | | | | | |
| Net income (loss) per common share: | | | | | | | |
| Basic | $ | 0.07 | | | $ | 0.65 | | | $ | (0.14) | | | $ | 0.40 | |
| Diluted | $ | 0.07 | | | $ | 0.65 | | | $ | (0.14) | | | $ | 0.40 | |
| | | | | | | |
| Weighted average shares outstanding: | | | | | | | |
| Basic | 9,047 | | 9,751 | | 9,232 | | | 9,913 | |
| | | | | | | |
| Diluted | 9,114 | | 9,751 | | 9,232 | | | 9,913 | |
See accompanying notes to condensed consolidated financial statements.
Ascent Industries Co.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| | | | | | | | | | | |
| Six Months Ended June 30, |
| 2026 | | 2025 |
| Operating activities | | | |
| Net income (loss) | $ | (1,310) | | | $ | 3,993 | |
| Income from discontinued operations, net of tax | — | | | 8,446 | |
| Net loss from continuing operations | (1,310) | | | (4,453) | |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | | |
| Depreciation expense | 1,737 | | | 1,870 | |
| Amortization expense | 490 | | | 306 | |
| Amortization of debt issuance costs | 100 | | | 179 | |
| Asset impairments | — | | | 1,622 | |
| Deferred income taxes | (487) | | | (90) | |
| Reduction of losses on accounts receivable | (961) | | | (506) | |
| | | |
| | | |
| Non-cash lease expense | (51) | | | (1) | |
| | | |
| Stock-based compensation expense | 366 | | | 222 | |
| Changes in operating assets and liabilities: | | | |
| Accounts receivable and advances | (6,458) | | | (4,908) | |
| Inventories | (1,134) | | | (939) | |
| Other assets and liabilities | (783) | | | (1,937) | |
| Accounts payable | 2,584 | | | (1,712) | |
| | | |
| Accrued expenses | (2,006) | | | 1,387 | |
| Accrued income taxes | 189 | | | 19 | |
| Net cash used in operating activities - continuing operations | (7,724) | | | (8,941) | |
| Net cash provided by operating activities - discontinued operations | — | | | 6,845 | |
| Net cash used in operating activities | (7,724) | | | (2,096) | |
| Investing activities | | | |
| Purchases of property, plant and equipment | (1,176) | | | (466) | |
| | | |
| Acquisitions, net of cash acquired | (13,536) | | | — | |
| Net cash used in investing activities - continuing operations | (14,712) | | | (466) | |
| Net cash provided by investing activities - discontinued operations | — | | | 54,425 | |
| Net cash provided by (used in) investing activities | (14,712) | | | 53,959 | |
| Financing activities | | | |
| Borrowings from credit facilities | 54,850 | | | 89,670 | |
| Proceeds from note payable | 997 | | | 1,085 | |
| Proceeds from exercise of stock options | 398 | | | — | |
| Payments on credit facilities | (54,850) | | | (89,670) | |
| Payments on note payable | (433) | | | (370) | |
| Principal payments on finance lease obligations | (163) | | | (144) | |
| | | |
| | | |
| Repurchase of common stock | (6,850) | | | (8,044) | |
| Net cash used in financing activities - continuing operations | (6,051) | | | (7,473) | |
| Net cash used in financing activities - discontinued operations | — | | | (19) | |
| Net cash used in financing activities | (6,051) | | | (7,492) | |
| Increase (decrease) in cash, cash equivalents and restricted cash | (28,487) | | | 44,371 | |
| | | |
| Cash, cash equivalents and restricted cash at beginning of period | 57,606 | | | 16,108 | |
| Cash, cash equivalents and restricted cash at end of period | $ | 29,119 | | | $ | 60,479 | |
See accompanying notes to condensed consolidated financial statements.
Ascent Industries Co.
Condensed Consolidated Statements of Shareholders' Equity (Unaudited)
(in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, 2026 |
| | | | | | | | | | | | | | |
| Common Stock | | Capital in Excess of Par Value | | Retained Earnings | | | | Treasury Stock | | Total |
| Shares | Amount | | | | | | Shares | | Amount | |
| Balance March 31, 2026 | 11,085 | | $ | 11,085 | | | $ | 47,656 | | | $ | 43,806 | | | | | 1,872 | | | $ | (20,906) | | | $ | 81,641 | |
| Net income | — | | — | | | — | | | 670 | | | | | | | — | | | 670 | |
Issuance of 6,507 shares of common stock from treasury | — | | — | | | (74) | | | — | | | | | (6) | | | 74 | | | — | |
| | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | | 209 | | | — | | | | | | | — | | | 209 | |
Repurchase of 209,868 shares of common stock | — | | — | | | — | | | — | | | | | 210 | | | (2,924) | | | (2,924) | |
| Balance as of June 30, 2026 | 11,085 | | $ | 11,085 | | | $ | 47,791 | | | $ | 44,476 | | | | | 2,076 | | | $ | (23,756) | | | $ | 79,596 | |
| | | | | | | | | | | | | | |
| Six Months Ended June 30, 2026 |
| | | | | | | | | | | | | | |
| Common Stock | | Capital in Excess of Par Value | | Retained Earnings | | | | Treasury Stock | | Total |
| Shares | Amount | | | | | | Shares | | Amount | |
| Balance at December 31, 2025 | 11,085 | | $ | 11,085 | | | $ | 48,276 | | | $ | 45,786 | | | | | 1,684 | | | $ | (18,155) | | | $ | 86,992 | |
| Net loss | — | | — | | | — | | | (1,310) | | | | | — | | | — | | | (1,310) | |
Issuance of 83,452 shares of common stock from treasury | — | | — | | | (917) | | | — | | | | | (83) | | | 917 | | | — | |
Exercise of stock options for 30,666 shares, net | — | | — | | | 66 | | | — | | | | | (31) | | | 332 | | | 398 | |
| Stock-based compensation | — | | — | | | 366 | | | — | | | | | — | | | — | | | 366 | |
Repurchase of 505,563 shares of common stock | — | | — | | | — | | | — | | | | | 506 | | | (6,850) | | | (6,850) | |
| Balance as of June 30, 2026 | 11,085 | | $ | 11,085 | | | $ | 47,791 | | | $ | 44,476 | | | | | $ | 2,076 | | | $ | (23,756) | | | $ | 79,596 | |
See accompanying notes to condensed consolidated financial statements.
Ascent Industries Co.
Condensed Consolidated Statement of Shareholders' Equity (Unaudited)
Continued
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, 2025 |
| | | | | | | | | | | | | | |
| Common Stock | | Capital in Excess of Par Value | | Retained Earnings | | | | Treasury Stock | | Total |
| Shares | Amount | | | | | | Shares | | Amount | |
| Balance March 31,2025 | 11,085 | | $ | 11,085 | | | $ | 47,335 | | | $ | 42,626 | | | | | 1,017 | | | $ | (9,890) | | | $ | 91,156 | |
| Net income | — | | — | | | — | | | 6,286 | | | | | | | — | | | 6,286 | |
Issuance of 5,948 shares of common stock from treasury | — | | — | | | (63) | | | — | | | | | (6) | | | 63 | | | — | |
| | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | | 103 | | | — | | | | | | | — | | | 103 | |
Repurchase of 644,171 shares of common stock | — | | — | | | — | | | — | | | | | 644 | | | (7,829) | | | (7,829) | |
| Balance as of June 30, 2025 | 11,085 | | 11,085 | | | 47,375 | | | 48,912 | | | | | 1,655 | | | (17,656) | | | $ | 89,716 | |
| | | | | | | | | | | | | | |
| Six Months Ended June 30, 2025 |
| | | | | | | | | | | | | | |
| Common Stock | | Capital in Excess of Par Value | | Retained Earnings | | | | Treasury Stock | | Total |
| Shares | Amount | | | | | | Shares | | Amount | |
| Balance at December 31, 2024 | 11,085 | | $ | 11,085 | | | $ | 47,339 | | | $ | 44,919 | | | | | 1,012 | | | $ | (9,798) | | | $ | 93,545 | |
| Net income | — | | — | | | — | | | 3,993 | | | | | | | — | | | 3,993 | |
Issuance of 18,586 shares of common stock from treasury | — | | — | | | (186) | | | — | | | | | (18) | | | 186 | | | — | |
| | | | | | | | | | | | | | |
| Stock-based compensation | — | | — | | | 222 | | | — | | | | | | | — | | | 222 | |
Repurchase of 660,993 shares of common stock | — | | — | | | — | | | — | | | | | 661 | | | (8,044) | | | (8,044) | |
| Balance as of June 30, 2025 | 11,085 | | 11,085 | | | 47,375 | | | 48,912 | | | | | 1,655 | | | (17,656) | | | $ | 89,716 | |
See accompanying notes to condensed consolidated financial statements.
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
Unless indicated otherwise, the terms "Company," "we," "us," and "our" refer to Ascent Industries Co. and its consolidated subsidiaries.
Note 1: Basis of Presentation
Basis of Financial Statement Presentation
The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not include all the disclosures normally required in annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The unaudited condensed consolidated financial statements, in the opinion of management, contain all normal recurring adjustments necessary to present a fair statement of the condensed consolidated balance sheets as of June 30, 2026, the statements of income (loss) and shareholders’ equity for the three and six months ended June 30, 2026 and 2025, and the statements of cash flows for the six months ended June 30, 2026 and 2025. The December 31, 2025 condensed consolidated balance sheet was derived from the audited financial statements.
These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "Annual Report"). The financial results for the interim periods may not be indicative of the financial results for the entire year as our future assessment of our current expectations could result in material impacts to our consolidated financial statements in future reporting periods.
Use of Estimates
The preparation of the Company's financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets, liabilities, sales and expenses, and related disclosures of contingent assets and liabilities. Significant items subject to such estimates and assumptions include the carrying value of property, plant and equipment; intangible assets; valuation allowances for receivables and deferred income tax assets and liabilities; liabilities for potential tax deficiencies; and, potential litigation claims and settlements as well as the fair value of the Company's financial instruments including cash, cash equivalents and restricted cash, accounts receivable, accounts payable, note payable and revolving line of credit.. The Company bases these estimates on historical results and various other assumptions believed to be reasonable, all of which form the basis for making estimates concerning the carrying value of assets and liabilities that are readily available from other sources. Actual results may differ from these estimates.
Significant Accounting Policies
Other than those listed below, there have been no significant changes in our significant accounting policies since the end of fiscal 2025.
Business Combinations - Business combinations are accounted for using the acquisition method of accounting. Under this method, the total consideration transferred to consummate the business combination is allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the transaction. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired, if any, and liabilities assumed.
Goodwill - Goodwill is the excess of the purchase price over the fair value of identifiable assets acquired, less fair value of liabilities assumed, in a business combination. The Company reviews goodwill for impairment at the reporting unit level, which is the operating segment level or one level below the operating segment level. Goodwill is not amortized but is evaluated for impairment at least annually on October 1 or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount may not be recoverable. The evaluation begins with a qualitative assessment to determine whether a quantitative impairment test is necessary. If, after assessing qualitative factors, we determine it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the quantitative goodwill impairment test is performed.
The quantitative goodwill impairment test used to identify potential impairment compares the fair value of a reporting unit with its carrying amount, including goodwill. Fair value represents the price a market participant would be willing to pay in a potential sale of the reporting unit and is based on a combination of an income approach, based on discounted future cash flows, and a market approach, based on market multiples applied to free cash flow. If the fair value exceeds the carrying value,
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
then no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. Any impairment identified is included within "goodwill impairment" in the unaudited consolidated statements of income (loss).
A reporting unit is an operating segment or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. During 2026, goodwill was allocated to the Specialty Chemicals reporting unit. The Company had no goodwill in fiscal 2025.
Accounting Pronouncements Recently Adopted
In December 2025, the Company adopted Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The amendments also require that all entities disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). The Company adopted this standard on a prospective basis and the adoption did not have a material effect on the consolidated financial statements or footnote disclosures.
Accounting Pronouncements Not Yet Adopted
In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. The ASU requires updated disclosures, in the notes to the financial statements, of specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose the amounts of purchases of inventory, employee compensation, depreciation, intangible asset amortization and depreciation, depletion, and amortization recognized as part of oil and gas producing activities included in relevant expense captions. The amendments also require disclosure of qualitative descriptions of amounts remaining in relevant expense captions that are not separately disaggregated and to disclose the total amount of selling expenses as well as the entity's definition of selling expenses. The ASU is effective for the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2027, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and footnote disclosures.
Recent accounting pronouncements pending adoption not discussed in this Form 10-Q are either not applicable to the Company or are not expected to have a material impact on the Company.
Note 2: Acquisitions
On May 4, 2026, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") to acquire 100% interest in substantially all the assets and certain specified liabilities of Midwest Graphic Sales, Inc. and Sigma Coating, Inc. (together, "Midwest") for purchase consideration of approximately $13.5 million, subject to certain working capital adjustments. The transaction closed simultaneously with the execution of the Purchase Agreement and was funded using cash on hand. Midwest is a specialty chemical formulator focused on the manufacturing and distribution of coatings, inks, and high-value packaging applications across food, pharmaceutical, personal care, and consumer end markets. The acquisition directly supports Ascent’s Chemicals-as-a-Service (“CaaS”) strategy and adds customer-embedded, formulation-driven demand across food, pharmaceutical, personal care, and consumer packaging applications, supported by customized solutions, strong margins, and long-tenured customer relationships that can be scaled across Ascent’s platform to drive margin expansion and accelerated growth.
The acquisition accounting resulted in the recognition, on a preliminary basis, of assets acquired and liabilities assumed on the acquisition date based on available information. The Company preliminarily recognized fair values of the assets acquired and liabilities assumed and recognized $4.7 million of goodwill and $7.7 million of intangible assets. As of June 30, 2026, the Company has not finalized acquisition accounting, including, but not limited to, the fair value of accounts receivable, accounts payable, accrued expenses, property, plant and equipment, and final purchase consideration. The acquisition accounting is subject to change as the Company continues to obtain and assess relevant information that existed as of the acquisition date.
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
The preliminary allocation of the total estimated purchase consideration is as follows:
| | | | | | | |
| (in thousands) | | | May 4, 2026 |
| | | |
| Accounts receivable, net | | | $ | 1,193 | |
| Inventories | | | 611 | |
| Prepaid expenses and other current assets | | | 7 | |
| Property, plant and equipment | | | 100 | |
| | | |
| Intangible assets | | | 7,665 | |
| Total identifiable assets acquired | | | 9,576 | |
| | | |
| Accounts payable | | | 658 | |
| Accrued expenses and other current liabilities | | | 117 | |
| Total identifiable liabilities assumed | | | 775 | |
| | | |
| Net identifiable assets acquired | | | 8,801 | |
| Total preliminary consideration transferred per ASC 805 | | | 13,536 | |
| Goodwill | | | $ | 4,735 | |
Goodwill primarily represents expected synergies from combining operations, acquired workforce, and other benefits that do not qualify for separate recognition. Goodwill is not expected to be deductible for income tax purposes. All of the $4.7 million acquired goodwill was assigned to the Company's Specialty Chemicals reportable segment
The intangible assets consist of trade names and trademarks of $0.3 million and customer relationships of $7.4 million, which will be amortized using an accelerated method over a period of 3 years and 20 years, respectively.
From the acquisition date through June 30, 2026, Midwest generated $1.9 million of net sales and no net income. Midwest's net income includes the impact of $0.3 million of intangible amortization from the acquisition date through June 30, 2026. For the three months ended June 30, 2026, total acquisition-related costs of $0.2 million were reported in selling, general and administrative expenses.
In connection with the acquisition of Midwest, the Company was required to fund $1.1 million of cash in escrow to be released after a holding period of 18 months, subject to post-closing employment obligations for certain acquired Midwest employees. See Note 16 for additional information on the Company's restricted cash. Pro Forma Financial Information
The following unaudited pro forma information shows the combined results of operations as if the acquisition had occurred as of the beginning of the periods presented. The unaudited pro forma information is presented for informational purposes only and may not reflect the actual results that would have been achieved and indicate future results.
| | | | | | | | | | | | | | | | | | | | | | | |
| (unaudited) | Three Months Ended June 30, | | Six Months Ended June 30, |
| (in thousands, except per share data) | 2026 | | 2025 | | 2026 | | 2025 |
| Pro forma net sales | $ | 26,551 | | | $ | 21,432 | | | $ | 49,169 | | | $ | 42,514 | |
| Pro forma net income (loss) | $ | 759 | | | $ | (2,609) | | | $ | (732) | | | $ | (4,232) | |
Note 3: Discontinued Operations
Divestiture of Bristol Metals
On March 12, 2025, the Company and its wholly-owned subsidiaries Synalloy Metals, Inc. ("Synalloy Metals") and Bristol Metals, LLC. ("BRISMET"), entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which they sold substantially all of the assets related to BRISMET to Bristol Pipe and Tube, Inc., a Delaware corporation and wholly-owned subsidiary of Ta Chen International, Inc. (the “Purchaser”). Ascent and Purchaser also entered into a Transition Services Agreement (the “TSA”) dated March 12, 2025, pursuant to which Ascent has agreed to provide certain transition services to Purchaser immediately after the closing for certain agreed upon transition periods. On April 4, 2025, the Company and Purchaser completed the transaction contemplated by the Purchase Agreement. The consideration for the transaction was
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
approximately $45 million of cash proceeds, of which $4.5 million was placed in an escrow account to be received in 18 months from the closing date. The escrow amount is presented within "Advances and other receivables" on the condensed consolidated balance sheets. During the three months ended September 30, 2025, the Company and Purchaser completed the measurement period closing adjustments under the terms of the Purchase Agreement resulting in a pretax gain on sale of $2.5 million. As result of the sale, BRISMET results of operations are classified under discontinued operations for all periods presented. Prior to the divestiture, BRISMET was reported under the Company's former Tubular Products segment.
Divestiture of American Stainless Tubing
On June 23, 2025, the Company and its wholly-owned subsidiary American Stainless Tubing, Inc. ("ASTI"), entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which they sold substantially all of the assets related to ASTI to First Tube, LLC., a Texas limited liability company and wholly-owned subsidiary of Triple-S Steel Holdings, Inc (the “Purchaser”). On June 30, 2025, the Company and Purchaser completed the transaction contemplated by the Purchase Agreement. The consideration for the transaction was approximately $16 million of cash proceeds, of which $0.8 million was placed in an escrow account to be received in 12 months from the closing date. The escrow amount is presented within "Advances and other receivables" on the condensed consolidated balance sheets. The sale resulted in a pretax gain on sale of $4.6 million. ASTI's results of operations are classified under discontinued operations for all periods presented. Prior to the divestiture, ASTI was reported under the Company's former Tubular Products segment.
The Company currently has no assets or liabilities related to discontinued operations.
The financial results are presented as income (loss) from discontinued operations, net of tax on the unaudited condensed consolidated statements of income (loss). The following table summarizes the results of the Company's discontinued operations:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| (in thousands) | 2026 | | 2025 | | 2026 | | 2025 |
| Net sales | $ | — | | | $ | 8,188 | | | $ | — | | | $ | 34,460 | |
| Cost of sales | — | | | 6,714 | | | — | | | 29,770 | |
| Gross profit | — | | | 1,474 | | | — | | | 4,690 | |
| | | | | | | |
| Selling, general and administrative expense | — | | | 498 | | | — | | | 1,888 | |
| Gain on sale of assets | — | | | (8,994) | | | — | | | (8,994) | |
| Acquisition costs and other | — | | | 1,323 | | | — | | | 3,421 | |
| | | | | | | |
| Income from discontinued operations before income taxes | — | | | 8,647 | | | — | | | 8,375 | |
| Income tax benefit | — | | | (86) | | | — | | | (71) | |
| Net income from discontinued operations | $ | — | | | $ | 8,733 | | | $ | — | | | $ | 8,446 | |
Note 4: Revenue Recognition
Revenue is generated primarily from contracts to produce, ship and deliver specialty chemical products or through distribution arrangements with our customers. Revenues are primarily recognized when control of the promised goods or services is transferred to our customers upon shipment, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. For certain distribution arrangements, revenue is recognized gross, as principal, when control of the promised goods or services is transferred to our customers upon delivery, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The Company's revenues are derived from contracts with customers where performance obligations are satisfied at a point-in-time or over-time. For certain contracts under which the Company produces product with no alternative use and for which the Company has an enforceable right to payment during the production cycle, product in which the material is customer owned or in which the customer simultaneously consumes the benefits throughout the production cycle, progress toward satisfying the performance obligation is measured using an output method of units produced. Certain customer arrangements consist of bill-and-hold characteristics under which transfer of control has been met (including the passing of title and significant risk and reward of ownership to the customers). Therefore, the customers can direct the use of the bill-and-hold inventory while we retain physical possession of the product until it is shipped to a customer at a point in time in the future.
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
Sales tax and other taxes we collect with revenue-producing activities are excluded from revenue. Shipping costs charged to customers are treated as fulfillment activities and are recorded in both revenue and cost of sales at the time control is transferred to the customer. Costs related to obtaining sales contracts are incidental and are expensed when incurred. Because customers are invoiced at the time title transfers and the Company’s right to consideration is unconditional at that time, the Company does not maintain contract asset balances. Additionally, the Company does not maintain material contract liability balances, as performance obligations for substantially all contracts are satisfied prior to customer payment for product. The Company offers industry standard payment terms.
The following table presents the Company's revenues, disaggregated by revenue source from continuing operations:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, | | |
| (in thousands) | 2026 | | 2025 | | 2026 | | 2025 | | | | |
Custom Manufacturing1 | $ | 14,999 | | | $ | 14,259 | | | $ | 30,306 | | | $ | 27,789 | | | | | |
Core Technology2 | 9,344 | | | 4,393 | | | 13,453 | | | 8,697 | | | | | |
Distribution3 | 1,324 | | | — | | | 1,324 | | | — | | | | | |
| Net sales | $ | 25,667 | | | $ | 18,652 | | | $ | 45,083 | | | $ | 36,486 | | | | | |
1Custom Manufacturing includes tolling, dedicated manufacturing and other manufacturing in which the customer formulation or intellectual property is owned by the customer
2Core technology includes product groups in which Ascent owns the right to the formulation or the intellectual property used in the manufacturing process
3Distribution includes product groups in which Ascent does not perform a manufacturing process over purchased material from the supplier
Performance obligations are supported by contracts with customers, providing a framework for the nature of the distinct goods, services or bundle of goods and services. The timing of satisfying the performance obligation is typically indicated by the terms of the contract. The following table represents the Company's revenue recognized at a point-in-time and over-time:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| (in thousands) | 2026 | | 2025 | | 2026 | | 2025 |
| Point-in-time | $ | 21,982 | | | $ | 11,685 | | | $ | 36,688 | | | $ | 25,317 | |
| Over-time | $ | 3,685 | | | $ | 6,967 | | | $ | 8,395 | | | $ | 11,169 | |
Note 5: Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, we use a three-tier valuation hierarchy based upon observable and non-observable inputs:
Level 1 - Unadjusted quoted prices that are available in active markets for identical assets or liabilities at the measurement date.
Level 2 - Significant other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including:
•Quoted prices for similar assets or liabilities in active markets;
•Quoted prices for identical or similar assets or liabilities in non-active markets;
•Inputs other than quoted prices that are observable for the asset or liability; and
•Inputs that are derived principally from or corroborated by other observable market data.
Level 3 - Significant unobservable inputs that cannot be corroborated by observable market data and reflect the use of significant management judgment. These values are generally determined using model-based techniques, including option pricing models, discounted cash flow models, probability weighted models, and Monte Carlo simulations.
The Company's financial instruments include cash, cash equivalents and restricted cash, accounts receivable, accounts payable, note payable and revolving line of credit.
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
During the three and six months ended June 30, 2026, the Company had no significant measurements of assets or liabilities at fair value on a non-recurring basis subsequent to their initial recognition. During the three and six months ended June 30,
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
2025, the Company's only significant measurements of assets or liabilities at fair value on a non-recurring basis subsequent to their initial recognition were certain right-of-use assets.
Right-of-use assets
During the second quarter of 2025, the Company incurred impairment charges of $1.6 million related to the write down of the right-of-use asset for the Company's Master lease associated with the former Munhall facility. Fair value was estimated by using a discounted cash flow method. The discounted future cash flows were determined based on future sublease rental rates, future sublease market conditions and a discount rate based on the Company's incremental borrowing rate. In the fourth quarter of 2025, the Company and its sale leaseback partner, Store, completed a lease assignment of the former Munhall facility to an unaffiliated third party and entered into Seventh Amended and Restated Master Lease agreement. See Note 10 for additional information on the Company's leases.
Fair Value of Financial Instruments
The fair values of cash, cash equivalents and restricted cash, accounts receivable, accounts payable and the Company's note payable approximated their carrying value because of the short-term nature of these instruments. The Company's revolving line of credit, which is based on a variable interest rate, are also reflected in the financial statements at carrying value which approximate fair values as of June 30, 2026. The carrying amount of cash, cash equivalents and restricted cash are considered Level 1 measurements. The carrying amounts of accounts receivable, accounts payable, note payable and revolving line of credit are considered Level 2 measurements. See Note 9 for further information on the Company's debt. Note 6: Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined by either specific identification or weighted average methods. The components of inventories from continuing operations are as follows:
| | | | | | | | | | | |
| (in thousands) | June 30, 2026 | | December 31, 2025 |
| Raw materials | $ | 8,700 | | | $ | 6,491 | |
| | | |
| Finished goods | 2,940 | | | 3,347 | |
| 11,640 | | | 9,838 | |
| Less: inventory reserves | (1,152) | | | (1,096) | |
| Inventories | $ | 10,488 | | | $ | 8,742 | |
Note 7: Property, Plant and Equipment
Property, plant and equipment from continuing operations consist of the following:
| | | | | | | | | | | |
| (in thousands) | June 30, 2026 | | December 31, 2025 |
| Land | $ | 518 | | | $ | 518 | |
| Leasehold improvements | 2,754 | | | 2,624 | |
| Buildings | 1,830 | | | 1,830 | |
| Machinery, fixtures and equipment | 41,183 | | | 40,120 | |
| Construction-in-progress | 972 | | | 332 | |
| 47,257 | | | 45,424 | |
| Less: accumulated depreciation and amortization | (31,564) | | | (29,662) | |
| Property, plant and equipment, net | $ | 15,693 | | | $ | 15,762 | |
The following table sets forth depreciation expense related to property, plant and equipment:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | | | Six Months Ended June 30, |
| (in thousands) | 2026 | | 2025 | | | | | | 2026 | | 2025 |
| Cost of sales | $ | 764 | | | $ | 838 | | | | | | | $ | 1,571 | | | $ | 1,760 | |
| Selling, general and administrative | 83 | | | 43 | | | | | | | 166 | | | 110 | |
| Total depreciation | $ | 847 | | | $ | 881 | | | | | | | $ | 1,737 | | | $ | 1,870 | |
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
Note 8: Intangible Assets and Deferred Charges
Intangible assets represent the fair value of intellectual, non-physical assets resulting from business acquisitions and are amortized over their estimated useful life using an accelerated method over a period ranging from three to 20 years. The weighted average amortization period for the customer relationships is approximately 17.52 years. Amortization expense is included in selling, general, and administrative expense on the unaudited condensed consolidated statements of income (loss).
The balance of intangible assets from continuing operations subject to amortization are as follows:
| | | | | | | | | | | | | | | | | |
| June 30, 2026 | | December 31, 2025 |
| (in thousands) | Gross Carrying Amount | Accumulated Amortization | | Gross Carrying Amount | Accumulated Amortization |
| Definite-lived intangible assets: | | | | | |
| Customer related | $ | 12,500 | | $ | (3,195) | | | $ | 5,100 | | $ | (2,779) | |
| Trademarks and trade names | 415 | | (56) | | | 150 | | (32) | |
| Other | 500 | | (156) | | | 500 | | (106) | |
| Total definite-lived intangible assets | $ | 13,415 | | $ | (3,407) | | | $ | 5,750 | | $ | (2,917) | |
Estimated amortization expense related to intangible assets for the next five years are as follows:
| | | | | | | | |
| (in thousands) | | | | |
| Remainder of 2026 | $ | 1,178 | | | | |
| 2027 | 1,894 | | | | |
| 2028 | 1,445 | | | | |
| 2029 | 1,129 | | | | |
| 2030 | 891 | | | | |
| 2031 | 727 | | | | |
| Thereafter | $ | 2,744 | | | | |
Deferred charges represent debt issuance costs and are amortized over their estimated useful lives using the straight-line method over a period of 2.5 years.
The balance of deferred charges subject to amortization are as follows:
| | | | | | | | | | | |
| (in thousands) | June 30, 2026 | | December 31, 2025 |
| Deferred charges, gross | $ | 506 | | | $ | 506 | |
| Accumulated amortization of deferred charges | (205) | | | (105) | |
| Deferred charges, net | $ | 301 | | | $ | 401 | |
Note 9: Debt
Short-term debt
On May 29, 2026, the Company entered into a note payable in the amount of $1.0 million with an annual interest rate of 2.57% maturing April 1, 2027. The agreement is associated with the financing of the Company's insurance premiums in the current term year. As of June 30, 2026, the outstanding balance was $1.0 million.
Credit Facilities
On December 10, 2025, the Company entered into a Limited Waiver, Consent and Sixth Amendment to Credit Agreement and Omnibus Amendment to Loan Documents with BMO Bank N.A. and the other lenders under the Company’s credit facility (the “Sixth Credit Facility Amendment”). The Sixth Credit Facility Amendment contained a consent for (a) the Company entering into the assignment of the lease for the Company’s former Munhall facility to a new tenant, and (b) certain organizational changes relating to an internal restructuring of the Company’s chemical manufacturing businesses, including (i) updates to the names of the Company’s chemical manufacturing businesses designed to provide for more consistent branding
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
across its manufacturing locations and (ii) the formation of a new holding company named Ascent Chemicals, LLC (“Ascent Chemicals”) to own all of the Company’s chemical manufacturing businesses. The Sixth Credit Facility Amendment also added Ascent Chemicals as a loan party to the credit facility. In addition, the Credit Facility Amendment provided a limited waiver of an event of default that occurred under the credit facility due to the Company’s repurchase of shares in an aggregate amount that exceeded the threshold set forth in Section 8.06(c) of the credit facility. The lenders under the credit facility have not accelerated any obligations of Ascent as a result of such event of default and will no longer have any such acceleration rights as a result of the limited waiver. The maximum revolving loan commitment under the credit facility remains $30 million with an interest rate between 1.85% and 2.35%, depending on average availability under the credit facility and the Company's consolidated fixed charge coverage ratio. The term of the credit facility remains through December 31, 2027.
We have pledged all of our accounts receivable, inventory, and certain machinery and equipment as collateral for the Credit Agreement. Availability under the Credit Agreement is subject to the amount of eligible collateral as determined by the lenders' borrowing base calculations. Amounts outstanding under the revolving line of credit currently bear interest at (a) the Base Rate (as defined in the Credit Agreement) plus 0.75%, or (b) SOFR plus 1.75%. The Credit Agreement also provides an unused commitment fee based on the daily used portion of the credit facility.
Pursuant to the Fifth Credit Facility Amendment, the Company was required to pledge all of its tangible and intangible properties, including the stock and membership interests of its subsidiaries. The Fifth Credit Facility Amendment contains covenants requiring the maintenance of a minimum consolidated fixed charge coverage ratio if excess availability falls below the greater of (i) $4.5 million and (ii) 15% of the revolving credit facility. As of June 30, 2026, the Company was in compliance with all financial debt covenants.
The Company had no debt outstanding under its credit facilities as of June 30, 2026 and December 31, 2025.
As of June 30, 2026, the Company had $17.9 million of remaining availability under its credit facilities.
Note 10: Leases
The Company's portfolio of leases contains both finance and operating leases that relate to real estate and manufacturing equipment. Substantially all of the value of the Company's leased plants and facilities relate to the Master Lease with Store Master Funding XII, LLC (“Store”), an affiliate of Store Capital Corporation ("Store Capital"), that was entered into in 2016 and since amended, with the latest amendment occurring in 2025.
On April 4, 2025, the Company and Store entered into a Fifth Amended and Restated Master Lease Agreement (the "Fifth Master Lease") to remove the BRISMET facility and reduce the Company's rent pursuant to the Fourth Amended and Restated Master Lease Agreement between the parties dated August 28, 2024. The Fifth Master Lease was determined to be a lease modification that qualified for a remeasurement of the existing lease and not a separate contract. Upon modification of the Fifth Master Lease, the right-of-use asset and operating lease liability were remeasured using an incremental borrowing rate determined on the date of modification. As such, the Company recognized a decrease in the right-of-use asset and operating lease liability related to the Fifth Master Lease of $6.5 million and $7.0 million, respectively, and recognized a gain on the modification of $0.5 million, which is reported within operating expenses on the unaudited consolidated statements of income (loss).
On June 30, 2025, the Company and Store entered into a Sixth Amended and Restated Master Lease Agreement (the "Sixth Master Lease") to remove the ASTI facility and reduce the Company's rent pursuant to the Fifth Amended and Restated Master Lease Agreement between the parties dated April 4, 2025. The Sixth Master Lease was determined to be a lease modification that qualified for a remeasurement of the existing lease and not a separate contract. Upon modification of the Sixth Master Lease, the right-of-use asset and operating lease liability were remeasured using an incremental borrowing rate determined on the date of modification. As such, the Company recognized a decrease in the right-of-use asset and operating lease liability related to the Fifth Master Lease of $4.0 million. See Note 3 for additional information on the Company's divestitures of BRISMET and ASTI. In the fourth quarter of 2025, the Company and Store completed a lease assignment of the former Munhall facility to a unaffiliated third party. As a result, on November 14, 2025, Ascent and Store entered into a Seventh Amended and Restated Master Lease Agreement (the "Seventh Master Lease") to remove the former Munhall facility and reduce the Company's rent pursuant to the Sixth Amended and Restated Master Lease Agreement between the parties dated June 30, 2025. The Seventh Master Lease was determined to be a lease modification that qualified for a remeasurement of the existing lease and not a separate contract. Upon modification of the Sixth Master Lease, the right-of-use asset and operating lease liability were remeasured using an incremental borrowing rate determined on the date of modification. As such, the Company recognized a
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
decrease in the right-of-use asset and operating lease liability related to the Seventh Master Lease of $5.5 million and $7.2 million, respectively, resulting in a gain on modification of $1.7 million in the fourth quarter of 2025.
As of June 30, 2026, operating lease liabilities related to the master lease agreement with Store Capital totaled $11.4 million, or 89% of the total lease liabilities on the unaudited consolidated balance sheet.
During the three and six months ended June 30, 2026, the Company did not enter into any new finance lease agreements.
Operating and finance lease amounts from continuing operations included in the unaudited condensed consolidated balance sheets are as follows (in thousands):
| | | | | | | | | | | | | | | | | | | | |
| Classification | | Financial Statement Line Item | | June 30, 2026 | | December 31, 2025 |
| Long-term Assets | | Right-of-use assets, operating leases | | $ | 9,074 | | | $ | 9,368 | |
| Long-term Assets | | Property, plant and equipment | | 895 | | | 1,060 | |
| Current liabilities | | Current portion of lease liabilities, operating leases | | 754 | | | 712 | |
| Current liabilities | | Current portion of lease liabilities, finance leases | | 340 | | | 331 | |
| Non-current liabilities | | Non-current portion of lease liabilities, operating leases | | 11,105 | | | 11,496 | |
| Non-current liabilities | | Non-current portion of lease liabilities, finance leases | | 635 | | | 808 | |
Total Lease Cost
Individual components of the total lease cost incurred by the Company are as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| (in thousands) | 2026 | | 2025 | | 2026 | | 2025 |
Operating lease cost1 | $ | 359 | | | $ | 768 | | | $ | 718 | | | $ | 1,721 | |
| Finance lease cost: | | | | | | | |
| Amortization of right-of-use assets | 82 | | | 75 | | | 165 | | | 151 | |
| Interest on finance lease liabilities | 15 | | | 18 | | | 31 | | | 36 | |
| Sublease income | (146) | | | (114) | | | (357) | | | (261) | |
| Total lease cost | $ | 310 | | | $ | 747 | | | $ | 557 | | | $ | 1,647 | |
1Includes short term leases, which are immaterial
Reduction in carrying amounts of right-of-use assets held under finance leases is included in depreciation expense. Minimum rental payments under operating leases are recognized on a straight-line method over the term of the lease including any periods of free rent and are included in selling, general, and administrative expense on the unaudited condensed consolidated statements of income (loss).
The Company currently subleases the former Palmer and Specialty Pipe & Tube ("SPT") facilities and records cash receipts related to the subleases in other expense (income) on the unaudited condensed consolidated statements of income (loss).
Future expected cash receipts from the Company's sublease as of June 30, 2026 are as follows: | | | | | |
| (in thousands) | Sublease Receipts |
| Remainder of 2026 | $ | 299 | |
| 2027 | 606 | |
| 2028 | 618 | |
| 2029 | 631 | |
| 2030 | 643 | |
| Thereafter | 3,954 | |
| Total sublease receipts | $ | 6,751 | |
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
Maturity of Leases
The amounts of undiscounted future minimum lease payments under leases in continuing operations as of June 30, 2026 are as follows:
| | | | | | | | | | | |
| (in thousands) | Operating | | Finance |
| Remainder of 2026 | $ | 782 | | | $ | 194 | |
| 2027 | 1,589 | | | 387 | |
| 2028 | 1,622 | | | 387 | |
| 2029 | 1,655 | | | 86 | |
| 2030 | 1,589 | | | 64 | |
| Thereafter | 9,567 | | | — | |
| Total undiscounted minimum future lease payments | 16,804 | | | 1,118 | |
| Imputed interest | (4,945) | | | (143) | |
| Present value of lease liabilities | $ | 11,859 | | | $ | 975 | |
Lease Term and Discount Rate
| | | | | | | | | | | |
| Weighted-average remaining lease term | June 30, 2026 | | December 31, 2025 |
| Operating leases | 10.02 years | | 10.50 years |
| Finance leases | 2.74 years | | 3.23 years |
| Weighted-average discount rate | | | |
| Operating leases | 7.19 | % | | 7.18 | % |
| Finance leases | 5.94 | % | | 5.94 | % |
Note 11: Shareholders' Equity
Share Repurchase Program
On December 19, 2025, the Board of Directors authorized a new share repurchase program allowing for repurchase of up to 2.0 million shares of the Company's outstanding common stock over 24 months. The shares will be purchased from time to time at prevailing market prices, through open market or privately negotiated transactions, depending on market conditions. Under the program, the purchases will be funded from available working capital, and the repurchased shares will be returned to the status of authorized, but unissued shares of common stock or held in treasury. There is no guarantee as to the exact number of shares that will be repurchased by the Company, and the Company may discontinue purchases at any time that management determines additional purchases are not warranted. As of June 30, 2026, the Company has 1,492,941 shares of its share repurchase authorization remaining.
Shares repurchased for the three and six months ended June 30, 2026 and 2025 were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2026 | | 2025 | | 2026 | | 2025 |
Number of shares repurchased1 | 209,868 | | | 644,171 | | | 505,563 | | | 660,993 | |
| Average price per share | $ | 13.80 | | | $ | 12.15 | | | $ | 13.29 | | | $ | 12.17 | |
Total cost of shares repurchased2 | $ | 2,924,245 | | | $ | 7,848,761 | | | $ | 6,849,961 | | | $ | 8,063,383 | |
1Share repurchases in excess of issuances are subject to a 1% excise tax, which is included as part of the cost basis of the shares acquired
2Includes broker commissions paid as part of repurchase transactions
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
Note 12: Earnings Per Share
The following table sets forth the computation of basic and diluted income (loss) per share:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| (in thousands, except per share data) | 2026 | | 2025 | | 2026 | | 2025 |
| Numerator: | | | | | | | |
| Net income (loss) from continuing operations | $ | 670 | | | $ | (2,447) | | | $ | (1,310) | | | $ | (4,453) | |
| Net income from discontinued operations | $ | — | | | $ | 8,733 | | | $ | — | | | $ | 8,446 | |
| Net income (loss) | $ | 670 | | | $ | 6,286 | | | $ | (1,310) | | | $ | 3,993 | |
| Denominator: | | | | | | | |
| Weighted-average common shares outstanding | 9,047 | | | 9,751 | | | 9,232 | | | 9,913 | |
| Effect of dilutive securities: | | | | | | | |
| Employee stock options and stock grants | 67 | | | — | | | — | | | — | |
| Weighted-average common shares, as adjusted | 9,114 | | | 9,751 | | | 9,232 | | | 9,913 | |
| | | | | | | |
| Net income (loss) per share from continuing operations: | | | | | | | |
| Basic | $ | 0.07 | | | $ | (0.25) | | | $ | (0.14) | | | $ | (0.45) | |
| Diluted | $ | 0.07 | | | $ | (0.25) | | | $ | (0.14) | | | $ | (0.45) | |
| | | | | | | |
| Net income per share from discontinued operations: | | | | | | | |
| Basic | $ | — | | | $ | 0.90 | | | $ | — | | | $ | 0.85 | |
| Diluted | $ | — | | | $ | 0.90 | | | $ | — | | | $ | 0.85 | |
| | | | | | | |
| Net income (loss) per share: | | | | | | | |
| Basic | $ | 0.07 | | | $ | 0.65 | | | $ | (0.14) | | | $ | 0.40 | |
| Diluted | $ | 0.07 | | | $ | 0.65 | | | $ | (0.14) | | | $ | 0.40 | |
The diluted earnings (loss) per share calculations exclude the effect of potentially dilutive shares when the inclusion of those shares in the calculation would have an anti-dilutive effect. The Company had 0.1 million shares that were anti-dilutive for the three and six months ended June 30, 2026 and 2025, respectively.
Note 13: Income Taxes
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. The Company is no longer subject to U.S. federal examinations for years before 2022 or state examinations for years before 2021. During the three and six months ended June 30, 2026 and 2025, the Company did not identify nor reserve for any unrecognized tax benefits.
The effective tax rate for continuing operations was (869.2)% and 27.1% for the three and six months ended June 30, 2026, respectively. The three months ended June 30, 2026 effective tax rate was lower than the U.S. statutory rate of 21.0%, primarily due to changes in forecasted income (loss) and the resulting changes in the valuation allowance on federal and state deferred tax assets. The six months ended June 30, 2026 effective tax rate was higher than the U.S. statutory rate of 21.0% primarily due to changes in the valuation allowance over federal and U.S. state deferred tax assets.
The effective tax rate for continuing operation was 2.1% and 2.0% for the three and six months ended June 30, 2025, respectively. The three and six months ended June 30, 2025 effective tax rate was lower than the U.S. statutory rate of 21.0% primarily due to the valuation allowance over federal and U.S state deferred tax assets.
Note 14: Commitments and Contingencies
From time to time, we are involved in various legal proceedings arising from the normal course of business activities. We are not presently a party to any other such litigation the outcome of which, we believe, if determined adversely to us, would
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
individually, or taken together, have a material adverse effect on our business, operating results, cash flows, or financial condition. Defending such proceedings is costly and can impose a significant burden on management and employees. We may receive unfavorable preliminary or interim rulings in the course of litigation, and there can be no assurances that favorable final outcomes will be obtained.
Note 15: Industry Segments
Ascent Industries Co. has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company’s plants involved in the production and distribution of specialty chemicals and produces critical ingredients and process aids across oil and gas, energy, household, industrial and institutional (“HII”), personal care, coatings, adhesives, sealants and elastomers (“CASE”), agriculture, water treatment, pulp and paper, construction, automotive, and other industrial markets.
The chief executive officer, who is also the chief operating decision maker (CODM), evaluates performance and determines resource allocations based on a number of factors, the primary measures being gross margin and segment net income (loss). The accounting principles applied at the operating segment level are the same as those applied at the consolidated financial statement level. The significant expense categories and amounts below align with the segment-level information that is regularly provided to the CODM. Intersegment sales and transfers are eliminated at the corporate consolidation level.
The following table summarizes certain information regarding segments of the Company's continuing operations:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, 2026 | | Six Months Ended June 30, 2026 |
| (in thousands) | | Specialty Chemicals | | Corporate & Other1 | | Total Continuing Operations | | Specialty Chemicals | | Corporate & Other1 | | Total Continuing Operations |
| Net sales | | $ | 25,667 | | | $ | — | | | $ | 25,667 | | | $ | 45,083 | | | $ | — | | | $ | 45,083 | |
| Cost of goods sold - material | | 13,443 | | | — | | | 13,443 | | | 21,799 | | | — | | | 21,799 | |
Cost of goods sold - other2 | | 5,882 | | | — | | | 5,882 | | | 13,354 | | | — | | | 13,354 | |
| Depreciation | | 794 | | | — | | | 794 | | | 1,570 | | | — | | | 1,570 | |
| Gross profit | | 5,548 | | | — | | | 5,548 | | | 8,360 | | | — | | | 8,360 | |
| Research and development | | 107 | | | — | | | 107 | | | 170 | | | — | | | 170 | |
Selling, general and administrative expense3 | | 4,388 | | | 633 | | | 5,021 | | | 9,113 | | | 780 | | | 9,893 | |
| Depreciation and amortization | | 413 | | | 93 | | | 506 | | | 571 | | | 186 | | | 757 | |
| Acquisition costs and other | | — | | | 176 | | | 176 | | | — | | | 177 | | | 177 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| Interest expense (income), net | | 13 | | | (168) | | | (155) | | | 26 | | | (474) | | | (448) | |
| Income taxes | | — | | | (601) | | | (601) | | | — | | | (487) | | | (487) | |
| Other expense (income) | | (29) | | | (147) | | | (176) | | | (34) | | | (358) | | | (392) | |
| Net income (loss) | | $ | 656 | | | $ | 14 | | | $ | 670 | | | $ | (1,486) | | | $ | 176 | | | $ | (1,310) | |
| | | | | | | | | | | | |
Geographic sales4 | | | | | | | | | | | | |
| United States | | $ | 24,473 | | | $ | — | | | $ | 24,473 | | | $ | 43,303 | | | $ | — | | | $ | 43,303 | |
| Honduras | | 278 | | | — | | | 278 | | | 450 | | | — | | | 450 | |
| Mexico | | 402 | | | — | | | 402 | | | 405 | | | — | | | 405 | |
| Canada | | 209 | | | — | | | 209 | | | 391 | | | — | | | 391 | |
| Colombia | | 151 | | | — | | | 151 | | | 263 | | | — | | | 263 | |
| Other | | $ | 154 | | | $ | — | | | $ | 154 | | | $ | 271 | | | $ | — | | | $ | 271 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, 2025 | | Six Months Ended June 30, 2025 |
| (in thousands) | | Specialty Chemicals | | Corporate & Other1 | | Total Continuing Operations | | Specialty Chemicals | | Corporate & Other1 | | Total Continuing Operations |
| Net sales | | $ | 18,652 | | | $ | — | | | $ | 18,652 | | | $ | 36,486 | | | $ | — | | | $ | 36,486 | |
| Cost of goods sold - material | | 8,814 | | | — | | | 8,814 | | | 17,177 | | | — | | | 17,177 | |
Cost of goods sold - other2 | | 4,816 | | | (682) | | | 4,134 | | | 9,622 | | | — | | | 9,622 | |
| Depreciation | | 835 | | | 3 | | | 838 | | | 1,754 | | | — | | | 1,754 | |
| Gross profit | | 4,187 | | | 679 | | | 4,866 | | | 7,933 | | | — | | | 7,933 | |
| | | | | | | | | | | | |
Selling, general and administrative expense3 | | 2,476 | | | 3,609 | | | 6,085 | | | 5,180 | | | 5,540 | | | 10,720 | |
| Depreciation and amortization | | 196 | | | 163 | | | 359 | | | 392 | | | 203 | | | 595 | |
| Acquisition costs and other | | — | | | 31 | | | 31 | | | 92 | | | 176 | | | 268 | |
| Asset impairment | | — | | | 1,622 | | | 1,622 | | | — | | | 1,622 | | | 1,622 | |
| Gain on lease modification | | — | | | (544) | | | (544) | | | — | | | (544) | | | (544) | |
| Interest expense (income), net | | 16 | | | (31) | | | (15) | | | 32 | | | 67 | | | 99 | |
| Income taxes | | — | | | (89) | | | (89) | | | — | | | (89) | | | (89) | |
| Other expense (income) | | — | | | (136) | | | (136) | | | — | | | (285) | | | (285) | |
| Net income (loss) | | $ | 1,499 | | | $ | (3,946) | | | $ | (2,447) | | | $ | 2,237 | | | $ | (6,690) | | | $ | (4,453) | |
| | | | | | | | | | | | |
Geographic sales4 | | | | | | | | | | | | |
| United States | | $ | 17,450 | | | $ | — | | | $ | 17,450 | | | $ | 34,093 | | | $ | — | | | $ | 34,093 | |
| Mexico | | 213 | | | — | | | 213 | | | 686 | | | — | | | 686 | |
| Canada | | 200 | | | — | | | 200 | | | 424 | | | — | | | 424 | |
| Colombia | | 166 | | | — | | | 166 | | | 303 | | | — | | | 303 | |
| The Netherlands | | 336 | | | — | | | 336 | | | 370 | | | — | | | 370 | |
| Honduras | | — | | | — | | | — | | | 270 | | | — | | | 270 | |
| Costa Rica | | 144 | | | — | | | 144 | | | 172 | | | — | | | 172 | |
| Other | | $ | 143 | | | $ | — | | | $ | 143 | | | $ | 168 | | | $ | — | | | $ | 168 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | |
| As of |
| (in thousands) | June 30, 2026 | | December 31, 2025 |
| Identifiable assets | | | |
| Specialty Chemicals | $ | 61,064 | | | $ | 37,303 | |
| | | |
| Corporate and other | 45,252 | | | 74,634 | |
| | | |
| $ | 106,316 | | | $ | 111,937 | |
1Corporate & Other includes corporate overhead expenses and ongoing expenses for properties under the Master Lease not assigned to a segment in which the Company is the responsible party.
2Cost of good sold - other includes manufacturing labor and overhead expenses, repair and maintenance expense, shipping expense, scrap and shrinkage expense, and other operational manufacturing overhead expenses.
3Selling, general and administrative expenses include sales and administrative salaries, wages and benefits and overhead expenses, professional fees, corporate overhead allocation expense and other administrative overhead expenses.
4Geographic sales are attributed to countries based on the location of the customer.
Ascent Industries Co.
Notes to Consolidated Financial Statements (Unaudited)
Note 16: Restricted Cash
Amounts included in restricted cash represent those required to be set aside for the escrow agreement associated with the Midwest acquisition. The escrow agreement has a holding period of 18 months, subject to post-closing employment obligations for certain acquired Midwest employees. Restricted cash is included in other non-current assets on the unaudited condensed consolidated balance sheets.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited consolidated statement of cash flows.
| | | | | | | | | | | |
| As of June 30, |
| 2026 | | 2025 |
| Cash and cash equivalents | $ | 28,069 | | | $ | 60,479 | |
| Restricted cash in other noncurrent assets | 1,050 | | | — | |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $ | 29,119 | | | $ | 60,479 | |
Note 17: Supplemental Disclosure
Net interest expense is comprised of the following:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, | | |
| (in thousands) | 2026 | | 2025 | | 2026 | | 2025 | | | | |
| Credit facilities | $ | 104 | | | $ | 175 | | | $ | 208 | | | $ | 271 | | | | | |
| Lease obligations | 15 | | | 18 | | | 31 | | | 36 | | | | | |
| Interest income | (275) | | | (208) | | | (689) | | | (208) | | | | | |
| Other | 1 | | | — | | | 2 | | | — | | | | | |
| Interest expense (income), net | $ | (155) | | | $ | (15) | | | $ | (448) | | | $ | 99 | | | | | |
Supplemental disclosures of cash flow information:
| | | | | | | | | | | |
| Six Months Ended June 30, |
| 2026 | | 2025 |
| Cash paid for interest | $ | 88 | | | $ | 121 | |
| Cash paid for income taxes, net | 84 | | | — | |
| | | |
| Noncash Investing Activities: | | | |
| Capital expenditures, not yet paid | $ | 393 | | | $ | 57 | |
Note 18: Subsequent Events
On July 17, 2026, the Company entered into an Omnibus Joinder to Loan Documents with BMO Bank N.A. and the other lenders under the Company’s credit facility (the “Credit Facility Amendment”). The Credit Facility Amendment was entered into in connection with the Company's acquisition of Midwest. In connection with the acquisition, the Company formed Ascent Chemicals - MGS, LLC, a wholly-owned subsidiary, to hold the acquired business and the related assets. Pursuant to the amendment, the Credit Agreement was amended to reflect the addition of Ascent Chemicals - MGS, LLC as a loan party and to make certain related conforming changes, including updates to the schedules and exhibits thereto. The maximum revolving loan commitment under the credit facility remains $30 million with an interest rate between 1.85% and 2.35%, depending on average availability under the credit facility and the Company's consolidated fixed charge coverage ratio. The term of the credit facility remains through December 31, 2027. See Note 9 for additional information on the Company's credit facilities.
In July 2026, the Company received the $0.8 million of funds previously held in escrow related to the ASTI divestiture. See Note 3 for additional information on the Company's discontinued operations.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
This discussion and analysis summarizes the significant factors affecting our consolidated operating results, liquidity, and capital resources during the three and six months ended June 30, 2026 and 2025, respectively. We intend for this discussion to provide the reader with information that will assist in understanding our financial statements, the changes in certain key items in those financial statements from year to year, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our financial statements. This discussion and analysis should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements that are included in our Annual Report on Form 10-K for the year ended December 31, 2025 (the Annual Report), as well as the condensed consolidated financial statements (unaudited) and notes to the condensed consolidated financial statements (unaudited) contained in this report. Unless otherwise specified, all comparisons made are to the corresponding period of 2025. This discussion and analysis is presented in five sections:
•Executive Overview
•Results of Operations and Non-GAAP Financial Measures
•Liquidity and Capital Resources
•Material Cash Requirements from Contractual and Other Obligations
•Critical Accounting Policies and Estimates
Executive Overview
Ascent Industries Co. is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. Ascent Industries Co. was incorporated in 1958 as the successor to a chemical manufacturing business founded in 1945 known as Blackman Uhler Industries Inc.
The Company has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment produces critical ingredients and process aids for the oil & gas, household, industrial and institutional ("HII"), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.
The second quarter represented an important inflection point in Ascent's evolution. Despite continued challenges across the broader specialty chemicals market, our legacy business delivered organic growth well above both the market and many of our peers, reflecting disciplined commercial and operational execution. At the same time, the acquisition of Midwest Graphic Sales has exceeded our expectations, delivering earnings accretion from day one and integrating ahead of schedule. Together, these results reinforce our confidence that the strategic roadmap we have been executing is creating a stronger, higher-quality specialty chemicals platform.
Macroeconomic Events
We continue to monitor macroeconomic trends and uncertainties such as key material inflation, the effects of recently implemented tariffs, and the potential imposition of modified or additional tariffs, which may have adverse effects on net sales and profitability. Following the February 20, 2026, Supreme Court ruling regarding the imposition of tariffs under the International Emergency Economic Powers Act (IEEPA), U.S. Customs and Border Protection is issuing refunds for tariffs previously paid under IEEPA. Concurrently, the Administration imposed a temporary 10% general tariff under Section 122 of the Trade Act of 1974 subject to several exemptions, including the import into the United States of certain aerospace products. As a result of the tariffs announced by the U.S. presidential administration and continued tariff modifications or the imposition of tariffs or export controls by other countries, we have worked with our suppliers to mitigate supply chain challenges, cost volatility, and consumer and economic uncertainty due to rapid changes in global trade policies. Much of our raw material used in production is domestically sourced and we are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and additional cost savings efforts. Economic pressures on customers and consumers, including the challenges of inflation and the effects of increased tariffs, may negatively affect our net sales and profitability in the future.
Geopolitical conflicts, including the continuation or escalation of ongoing tensions and military conflicts in the Middle East may also disrupt business operations of suppliers and/or customers, causing supply chain constraints or delays, increased pricing or delayed spending by our customers. The full impact of such events are not known at this time, but they could have a material adverse impact on our business, financial condition, results of operations, and stock price.
These developments did not have a material impact on our financial position, results of operations and cash flows during the three and six months ended June 30, 2026.
Results of Operations
Consolidated Performance Summary
Consolidated net sales for the second quarter of 2026 were $25.7 million, an increase of $7.0 million, or 37.6%, compared to net sales for the second quarter of 2025. The increase in net sales was primarily driven by a 15.2% increase in pounds shipped and a 23.0% increase in average selling prices.
Consolidated net sales for the six months ended June 30, 2026 were $45.1 million, an increase of $8.6 million, or 23.6%, compared to net sales for the six months ended June 30, 2025. The increase in net sales was primarily driven by an 11.5% increase in pounds shipped and a 14.6% increase in average selling prices.
For the second quarter of 2026, consolidated gross profit increased 14.0% to $5.5 million, or 21.6% of sales, compared to $4.9 million, or 26.1% of sales in the second quarter of 2025. For the six months ended June 30, 2026, consolidated gross profit increased 5.4% to $8.4 million, or 18.5% of sales, compared to $7.9 million, or 21.7% of sales in the six months ended June 30, 2025. The increase in dollars for the second quarter and first six months was primarily driven by increases in cost recovery in the period due to increased production, reductions in utilities and repairs and maintenance partially offset by increases in labor and overhead.
Consolidated selling, general, and administrative expense (SG&A) for the second quarter of 2026 decreased $0.9 million to $5.5 million, or 21.5% of sales, compared to $6.4 million, or 34.5% of sales in the second quarter of 2025. Consolidated selling, general, and administrative expense (SG&A) for the six months ended June 30, 2026 decreased $0.7 million to $10.7 million, or 23.6% of sales, compared to $11.3 million, or 31.0% of sales in the six months ended June 30, 2025. The decrease in SG&A expense for the second quarter of 2026 and six months ended June 30, 2026 was primarily driven by decreases in incentive bonus, professional fees and repairs and maintenance partially offset by increase in salaries, wages and benefits.
Consolidated operating loss in the second quarter of 2026 totaled $0.3 million compared to an operating loss of $2.7 million in the second quarter of 2025. Consolidated operating loss in the six months ended June 30, 2026 totaled $2.6 million compared to an operating loss of $4.7 million in the six months ended June 30, 2025. The operating loss decrease in the six months ended June 30, 2026 was primarily driven by aforementioned increase in gross profit and decrease in SG&A expense as well as decreases in asset impairments and gain on lease modification in the prior year not in the current year.
Specialty Chemicals
SG&A expense for the second quarter of 2026 was $4.8 million, or 18.7% of sales, compared to $2.7 million, or 14.3% of sales in the second quarter of 2025. SG&A expense for the six months ended June 30, 2026 was $9.7 million, or 21.5% of sales, compared to $5.6 million, or 15.3% of sales in the six months ended June 30, 2025. The increase in dollars for the three and six months ended June 30, 2026 was primarily driven by increases in corporate expense allocation, salaries, wages and benefits and amortization expense partially offset by decreases in incentive bonus.
Operating income decreased to $0.6 million for the second quarter of 2026 compared to operating income of $1.5 million for the second quarter of 2025. The current year decrease in operating income was primarily driven by the aforementioned increase in SG&A expense. Operating loss increased to $1.5 million for the six months ended June 30, 2026 compared to operating income of $2.3 million for the six months ended June 30, 2025. The current year increase in operating loss was primarily driven by the aforementioned increase in SG&A expense.
Corporate & Other Items
Unallocated corporate and other expenses for the second quarter of 2026 decreased $2.4 million, or 76.5%, to $0.7 million, or 2.8% of sales, compared to $3.1 million, or 16.6% of sales, in the prior year. The second quarter of 2026 decrease in dollars was primarily driven by increases corporate allocation as well as decreases in incentive bonus, professional fees, taxes and licenses partially offset by increases in salaries, wages and benefits.
Unallocated corporate and other expenses for the six months ended June 30, 2026 decreased $5.9 million, or 83.7%, to $1.1 million, or 2.5% of sales, compared to $7.0 million, or 19.2% of sales, in the prior year. The six months ended June 30, 2026 decrease in dollars was primarily driven by increases in corporate allocation to Chemicals locations as well as decreases in professional fees, taxes and licenses, incentive bonus and IT software costs partially offset by increases in salaries, wages and benefits and dues and subscriptions.
Interest income was $0.2 million for the second quarter of 2026 compared to diminimus interest income for the second quarter of 2025. Interest income was $0.5 million for the six months ended June 30, 2026 compared to interest expense of $0.1 million
for the six months ended June 30, 2025. The change was driven by a higher interest-bearing cash balance in the current year compared to the prior year. The Company had no debt outstanding under its credit facilities in either period.
The effective tax rate for continuing operations was (869.2)% and 27.1% for the three and six months ended June 30, 2026, respectively. The three months ended June 30, 2026 effective tax rate was lower than the U.S. statutory rate of 21.0%, primarily due to changes in forecasted income (loss) and the resulting changes in the valuation allowance on federal and state deferred tax assets. The six months ended June 30, 2026 effective tax rate was higher than the U.S. statutory rate of 21.0% primarily due to changes in the valuation allowance over federal and U.S. state deferred tax assets.
Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), we use the following non-GAAP financial measures: EBITDA and Adjusted EBITDA. Management believes that these non-GAAP measures are useful because they are key measures used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions as well as allow readers to compare the financial results between periods. Non-GAAP measures should not be considered as an alternative to any measure of performance or financial condition as promulgated under GAAP, and investors should consider the Company's performance and financial condition as reported under GAAP and all other relevant information when assessing the performance or financial condition of the Company. Non-GAAP measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results or financial condition as reported under GAAP.
EBITDA and Adjusted EBITDA
We define "EBITDA" as earnings before interest, income taxes, depreciation and amortization. We define "Adjusted EBITDA" as EBITDA further adjusted for the impact of non-cash and other items we do not consider in our evaluation of ongoing performance. These items include: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, shelf registration costs, loss on extinguishment of debt, retention costs and restructuring and severance costs from net income. We caution investors that amounts presented in accordance with our definitions of EBITDA and Adjusted EBITDA may not be comparable to similar measures disclosed by other companies because not all companies calculate EBITDA and Adjusted EBITDA in the same manner. We present EBITDA and Adjusted EBITDA because we consider them to be important supplemental measures of our performance and investors' understanding of our performance is enhanced by including these non-GAAP financial measures as a reasonable basis for comparing our ongoing results of operations.
Consolidated EBITDA and Adjusted EBITDA from continuing operations are as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| ($ in thousands) | 2026 | | 2025 | | 2026 | | 2025 |
| | | | | | | |
| Net income (loss) from continuing operations | $ | 670 | | | $ | (2,447) | | | $ | (1,310) | | | $ | (4,453) | |
| Adjustments: | | | | | | | |
| Interest expense (income), net | (155) | | | (15) | | | (448) | | | 99 | |
| | | | | | | | |
| Income taxes | (601) | | | (89) | | | (487) | | | (89) | |
| Depreciation | 877 | | | 893 | | | 1,737 | | | 1,870 | |
| Amortization | 373 | | | 153 | | | 490 | | | 306 | |
| EBITDA | 1,164 | | | (1,505) | | | (18) | | | (2,267) | |
| Acquisition costs and other | 176 | | | 31 | | | 177 | | | 268 | |
| | | | | | | | |
| Shelf registration costs | — | | | — | | | 14 | | | — | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Asset impairments | — | | | 1,622 | | | — | | | 1,622 | |
| | | | | | | | |
| Gain on lease modification | — | | | (544) | | | — | | | (544) | |
| Stock-based compensation | 137 | | | 86 | | | 270 | | | 120 | |
| Non-cash lease expense | (26) | | | (25) | | | (51) | | | (1) | |
| | | | | | | | |
| Restructuring and severance cost | — | | | — | | | 97 | | | — | |
| Adjusted EBITDA | $ | 1,451 | | | $ | (335) | | | $ | 489 | | | $ | (802) | |
| % of sales | 5.7 | % | | (1.8) | % | | 1.1 | % | | 2.2 | % |
Specialty Chemicals EBITDA and Adjusted EBITDA are as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| ($ in thousands) | 2026 | | 2025 | | 2026 | | 2025 |
| | | | | | | |
| Net income (loss) | $ | 656 | | | $ | 1,499 | | | $ | (1,486) | | | $ | 2,237 | |
| Adjustments: | | | | | | | |
| Interest expense, net | 13 | | | 15 | | | 25 | | | 32 | |
| Depreciation | 835 | | | 878 | | | 1,652 | | | 1,840 | |
| Amortization | 373 | | | 153 | | | 490 | | | 306 | |
| EBITDA | 1,877 | | | 2,545 | | | 681 | | | 4,415 | |
| Acquisition costs and other | — | | | — | | | — | | | 92 | |
| | | | | | | | |
| Stock-based compensation | 24 | | | — | | | 54 | | | — | |
| Non-cash lease expense | (15) | | | (5) | | | (30) | | | 3 | |
| Restructuring and severance costs | — | | | — | | | 38 | | | — | |
| Specialty Chemicals Adjusted EBITDA | $ | 1,886 | | | $ | 2,540 | | | $ | 743 | | | $ | 4,510 | |
| % of segment sales | 7.3 | % | | 13.6 | % | | 1.6 | % | | 12.4 | % |
Liquidity and Capital Resources
We closely manage our liquidity and capital resources. Our liquidity requirements depend on key variables, including level of investment required to support our business strategies, the performance of our business, capital expenditures, credit facilities and working capital management. Capital expenditures and share repurchases are a component of our cash flow and capital management strategy which we can adjust in response to economic and other changes in our business environment. We have a disciplined approach to capital allocation focusing on priorities that support our business and growth.
Sources of Liquidity
Funds generated by operating activities supplemented by our available cash and cash equivalents and our credit facilities are our most significant sources of liquidity. As of June 30, 2026, we held $28.1 million of cash and cash equivalents, as well as $17.9 million of remaining available capacity on our revolving line of credit. We believe our sources of liquidity will be sufficient to fund operations and anticipated capital expenditures as well as repay our debt obligations as they become due over the next 12 months and beyond.
Cash Flows
Cash flows from continuing operations were as follows:
| | | | | | | | | | | |
| Six Months Ended June 30, |
| (in thousands) | 2026 | | 2025 |
| Total cash used in: | | | |
| Operating activities | $ | (7,724) | | | $ | (8,941) | |
| Investing activities | (14,712) | | | (466) | |
| Financing activities | (6,051) | | | (7,473) | |
| Net decrease in cash, cash equivalents and restricted cash | $ | (28,487) | | | $ | (16,880) | |
Operating Activities
The decrease in cash used in operating activities for the six months ended June 30, 2026, compared to cash used in operating activities in the six months ended June 30, 2025, was primarily driven by decreases in net loss from $4.5 million in the six months ended June 30, 2025 to $1.3 million in the six months ended June 30, 2026 and changes in working capital. Changes in working capital can vary significantly depending on factors such as the timing of inventory production and purchases, customer payments of accounts receivable and payments to vendors in the regular course of business. Accounts payable increased operating cash flows by $2.6 million for the first six months of 2026, compared to a decrease of $1.7 million in the first six months of 2025. The change in accounts payable is primarily due to increased inventory purchases to match increases
in sales. Accounts receivable and advances decreased operating cash flows by $6.5 million in the first six months of 2026 compared to a $4.9 million decrease in the first six months of 2025. The decrease in cash generated by accounts receivable and advances is primarily driven by an increase in net sales in the current period and increased days sales outstanding in the current period. Inventory decreased operating cash flows for the first six months of 2026 by $1.1 million compared to a decrease of $0.9 million for the first six months of 2025. The change in inventory is primarily driven by higher inventory purchases in the first six months of 2026 compared to the first six months of 2025 coupled with and increase in days inventory outstanding year over year.
Investing Activities
Net cash used in investing activities primarily consists of transactions related to capital expenditures and acquisitions. The increase in cash used in investing activities for the six months ended June 30, 2026 compared to the cash used in investing activities for the six months ended June 30, 2025 was primarily due to the purchase of Midwest Graphic Sales in the second quarter of 2026 as well as increases in capital expenditures in the current year compared to the prior year.
Financing Activities
Net cash used in financing activities primarily consists of transactions related to our credit facilities and share repurchases. The decrease in cash used in financing activities for the six months ended June 30, 2026 compared to cash used in financing activities for the six months ended June 30, 2025 was primarily due to decreased repurchases of common stock in the current year. The Company had no debt outstanding under its credit facilities as of June 30, 2026 and December 31, 2025.
Short-term Debt
The Company has a note payable in the amount of $1.0 million with an annual interest rate of 2.57% maturing April 1, 2027, associated with the financing of the Company's insurance premium in 2026. As of June 30, 2026, the outstanding balance was $1.0 million.
Credit Facilities
On December 10, 2025, the Company entered into a Limited Waiver, Consent and Sixth Amendment to Credit Agreement and Omnibus Amendment to Loan Documents with BMO Bank N.A. and the other lenders under the Company’s credit facility (the “Sixth Credit Facility Amendment”). The maximum revolving loan commitment under the credit facility remains $30 million with an interest rate between 1.85% and 2.35%, depending on average availability under the credit facility and the Company's consolidated fixed charge coverage ratio. The term of the credit facility remains through December 31, 2027.
The Facility contains covenants requiring the maintenance of a minimum consolidated fixed charge coverage ratio if excess availability falls below the greater of (i) $4.5 million and (ii) 15% of the revolving credit facility. As of June 30, 2026, the Company was in compliance with all financial debt covenants. As of June 30, 2026, the Company had no principal payments outstanding under its credit facilities. See Note 9 in the unaudited notes to the consolidated financial statements for additional information on the Company's credit facilities. Share Repurchases and Dividends
We have a share repurchase program, authorized by the Company's Board of Directors, that is executed through purchases made from time to time at prevailing market prices, through open market or privately negotiated transactions, depending on market conditions. Shares repurchased are returned to status of authorized, but unissued shares of common stock or held in treasury. As of June 30, 2026, the Company has 1,492,941 shares of its share repurchase authorization remaining.
Shares repurchased for the three and six months ended June 30, 2026 and 2025 were as follows:
| | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | Six Months Ended June 30, |
| 2026 | | 2025 | 2026 | | 2025 |
| Number of shares repurchased | 209,868 | | | 644,171 | | 505,563 | | | 660,993 | |
| Average price per share | $ | 13.80 | | | $ | 12.15 | | $ | 13.29 | | | $ | 12.17 | |
| Total cost of shares repurchased | $ | 2,924,245 | | | $ | 7,848,761 | | $ | 6,849,961 | | | $ | 8,063,383 | |
At the end of each fiscal year the Board of Directors reviews the financial performance and capital needed to support future growth to determine the amount of cash dividend, if any, which is appropriate. In 2025, no dividends were declared or paid by the Company.
Other Financial Measures
Below are additional financial measures that we believe are important in understanding the Company's liquidity position from year to year. The metrics are defined as:
Liquidity Measure:
•Current ratio = current assets divided by current liabilities. The current ratio will be determined by the Company using generally accepted accounting principles, consistently applied.
Profitability Ratio:
•Return on average equity ("ROAE") = net income divided by the trailing 12-month average of equity. The ROAE will be determined by the Company using generally accepted accounting principles, consistently applied.
Results of these additional measures are as follows:
| | | | | | | | | | | | | | |
| | | | June 30, 2026 | | December 31, 2025 |
| Current ratio | | | | 4.3 | | 6.7 |
| | | | | | |
| Return on average equity | | | | (2.4)% | | (8.7)% |
Material Cash Requirements from Contractual and Other Obligations
As of June 30, 2026, our material cash requirements for our known contractual and other obligations were as follows:
•Operating and Finance Leases - The Company enters into various lease agreements for the real estate and manufacturing equipment used in the normal course of business. Operating and finance lease obligations were $12.8 million, with $1.1 million payable within 12 months. See Note 10 for further detail of our lease obligations and the timing of expected future payments. The Company has no off-balance sheet arrangements that are reasonably likely to have a material current or future effect on the Company's financial position, revenues, results of operations, liquidity, or capital expenditures. We expect capital spending to be as much as $3.0 million for the remainder of fiscal 2026.
Critical Accounting Policies and Estimates
We describe our significant accounting policies in Note 1, Summary of Significant Accounting Policies, in the notes to the consolidated financial statements presented in the Annual Report on Form 10-K for the year ended December 31, 2025. We discuss our critical accounting estimates in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, in the Annual Report on Form 10-K for the year ended December 31, 2025. Other than those listed below, there have been no significant changes in our significant accounting policies or critical accounting estimates since the end of fiscal 2025.
Business Combinations
Description
Business combinations are accounted for using the acquisition method of accounting in accordance with GAAP. Under this method, the total consideration transferred to consummate the business combination is allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the transaction.
Judgments and uncertainties involved in the estimate
The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired, if any, and liabilities assumed. Fair value determinations involve significant assumptions about highly subjective variables, including future cash flows, discount rates, customer attrition and expected business performance. There are also different valuation models and inputs for each component, the selection of which requires considerable judgment. Our estimates and assumptions may be based, in part, on the availability of listed market prices or other transparent market data. These determinations will affect the amount of amortization expense recognized in future periods as well the residual amount recognized as goodwill, if any, attributable to the transaction.
Effect if actual results differ from assumptions
We base our fair value estimates on assumptions we believe are reasonable, but recognize the assumptions are inherently uncertain. Depending on the size of the purchase price of a particular acquisition, the mix of intangible assets acquired and expected business performance, the purchase price allocation could be materially impacted by applying a different set of assumptions and estimates. Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results.
Goodwill
Description
Goodwill is the excess of the purchase price over the fair value of identifiable assets acquired, less fair value of liabilities assumed, in a business combination. The Company reviews goodwill for impairment at the reporting unit level, which is the operating segment level or one level below the operating segment level. A reporting unit is an operating segment or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. Goodwill is not amortized but is evaluated for impairment at least annually on October 1 or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount may not be recoverable. The evaluation begins with a qualitative assessment to determine whether a quantitative impairment test is necessary. If, after assessing qualitative factors, we determine it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the quantitative goodwill impairment test is performed.
Judgments and uncertainties involved in the estimate
We make various estimates and assumptions about our goodwill, including whether any potential impairment events have occurred. Examples of such events or changes in circumstances, many of which are subjective in nature, include the following:
•Significant negative industry or economic trends;
•A significant change in the use of the acquired assets or our strategy;
•A significant divestiture or other disposition activity;
•A significant decrease in the market value of the asset;
•A significant change in legal factors or the business climate that could affect the value of the asset; and
•A change in segment by one or more reporting unit
Additionally, we make estimates and assumptions regarding the inputs used to perform a quantitative assessment of our goodwill, if necessary, and the Company will perform a discounted cash flow analysis and a market multiple analysis. The discounted cash flow analysis includes management assumptions for expected sales growth, capital expenditures and overall operational forecasts. The market multiple analysis includes historical and projected performance, market capitalization, volatility and multiples for industry peers.
Effect if actual results differ from assumptions
We have not made any material changes in our methodology used to determine whether potential impairment events have occurred or any material changes in the estimates and assumptions used in our quantitative goodwill impairment testing. As of June 30, 2026, the Company's goodwill balance is $4.7 million.
Item 3. Quantitative and Qualitative Disclosures about Market Risks
We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act; therefore, we are not required to provide the information required by this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures” is defined in Rule 13a-15(e) of the Exchange Act as “controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms.” The Company’s disclosure controls and procedures are designed to ensure that material information relating to the Company and its consolidated subsidiaries is accumulated and communicated to its management, including its Chief Executive Officer and its Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures. The Company’s management, with the participation of its Chief Executive Officer and Chief Financial
Officer, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures as of June 30, 2026. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2026, because of the previously reported material weaknesses in internal control over financial reporting, as described below.
Previously Reported Material Weaknesses in Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15f-15(f). As reported in our 2025 Form 10-K, based upon the ongoing ineffectiveness of our IT general controls, we did not maintain effective internal control over financial reporting as of December 31, 2025 as a result of material weaknesses in the control environment. A material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Refer to our 2025 Form 10-K for a description of our material weaknesses.
Ongoing Remediation Efforts to Address Material Weaknesses
Our Board of Directors and management are committed to the continued implementation of remediation efforts to address the material weaknesses. The material weaknesses were first identified in 2021 and 2022 and while the Company has significantly improved its internal control over financial reporting, the material weaknesses remain un-remediated as of June 30, 2026 due to the continued IT general control ineffectiveness. During the three and six months ended June 30, 2026, management, with oversight from the Company's Audit Committee, continued executing a detailed plan for remediation which includes:
•Actively working with the third-party service organization to issue a SOC 1 report in fiscal 2026 to obtain the necessary assurance over an in-scope system critical to the Company's financial reporting processes. In addition, we are enhancing our monitoring controls and documentation to continue to strengthen our overall control environment.
•Maintaining corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility and accountability as well as maintaining a sufficient number of qualified resources in key personnel areas over the performance and maintenance of the Company's control environment.
•Continuing to engage an external advisor to assist with enhancing, designing, and implementing general information technology controls, including user access provisioning, cyber-security, and segregation of duties.
•Formalizing information technology policies and procedures to ensure that they are current and comprehensive and support the timely execution of information technology processes and control procedures.
•Maintaining review controls for inventory, revenue accounting, financial close processes and complex accounting to ensure accurate reporting and timely disclosures and ensuring evidence is appropriately retained.
•Maintaining effective controls for communicating and sharing information between the operations, accounting, information technology, sales, finance and legal departments to ensure that the accounting department is consistently provided with complete and adequate support, documentation and information, and that matters are resolved in a timely and effective manner.
The Audit Committee of the Board of Directors is monitoring management's ongoing remediation efforts. With the Audit Committee's oversight, management has dedicated significant resources and efforts to improve our internal control environment to remedy the identified material weaknesses. As we continue to evaluate and implement improvements to our internal control over financial reporting, our management may decide to take additional measures to address our control deficiencies or to modify the remediation efforts undertaken. Because the reliability of the internal control process requires repeatable execution, our material weaknesses cannot be considered fully remediated until all remedial processes and procedures (including additional remediation efforts identified by our senior management as necessary) have been implemented, each applicable control has operated for a sufficient period of time and management has concluded, through testing, that the controls are operating effectively. Until all identified material weaknesses are remediated, we will not be able to assert that our internal controls are effective.
Changes in Internal Control over Financial Reporting
Other than the ongoing remediation efforts described above, there have been no changes in the Company’s internal control over financial reporting during the three and six months ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.
PART II
Item 1. Legal Proceedings
It is not unusual for us and our subsidiaries to be involved in various unresolved legal actions, administrative proceedings and claims in the ordinary course of business involving, among other things, product liability, commercial, employment, workers' compensation, and environmental matters.. With respect to such lawsuits, claims and proceedings, the Company records reserves when it is probable a liability has been incurred and the amount of loss can be reasonably estimated. We cannot predict with any certainty the outcome of these unresolved legal actions or, in some cases, the range of possible loss or recovery. Information pertaining to legal proceedings can be found in Note 14 - Commitments and Contingencies in the notes to the unaudited condensed consolidated financial statements, and is incorporated by reference herein. Item 1A. Risk Factors
There were no material changes in our assessment of risk factors as discussed in Part I, Item 1A in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
The following table sets forth information with respect to purchases of the Company’s common stock on a trade date basis made during the three months ended June 30, 2026:
| | | | | | | | | | | | | | | | | | | | | | | |
| Period | Total Number of Shares Purchased | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Programs1 | | Number of Shares that May Yet Be Purchased under the Program |
| April 1, 2026 - April 30, 2026 | 163,586 | | | $ | 13.74 | | | 163,586 | | | 1,539,223 | |
| May 1, 2026 - May 31, 2026 | 45,782 | | | 14.03 | | | 45,782 | | | 1,493,441 | |
| June 1, 2026 - June 30, 2026 | 500 | | | 13.39 | | | 500 | | | 1,492,941 | |
| As of June 30, 2026 | 209,868 | | | $ | 13.80 | | | 209,868 | | | 1,492,941 | |
1On December 19, 2025, the Board of Directors authorized a new share repurchase program allowing for repurchase of up to 2.0 million shares of the Company's outstanding common stock. The stock repurchase program expires in 24 months and there is no guarantee to the exact number of shares that will be repurchased by the Company over that period. See Note 11 for additional information. Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
During the three and six months ended June 30, 2026, none of the Company’s directors or executive officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Regulation S-K, Item 408).
Item 6. Exhibits
| | | | | | | | | | | | | | | | |
| Exhibit No. | | Description | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| 101.INS* | | XBRL Instance Document | | | | | | | | |
| 101.SCH* | | XBRL Taxonomy Extension Schema | | | | | | | | |
| 101.CAL* | | XBRL Taxonomy Extension Calculation Linkbase | | | | | | | | |
| 101.LAB* | | XBRL Taxonomy Extension Label Linkbase | | | | | | | | |
| 101.PRE* | | XBRL Taxonomy Extension Presentation Linkbase | | | | | | | | |
| 101.DEF* | | XBRL Taxonomy Extension Definition Linkbase | | | | | | | | |
| 104 | | | Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101*) | | | | | | | | |
| * | | In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed "furnished" and not "filed." | | | | | | | | |
| | | | | | | | | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | |
| | |
| ASCENT INDUSTRIES CO. |
| (Registrant) |
| | | |
| | | |
Date: | August 4, 2026 | By: | /s/ J. Bryan Kitchen |
| | | J. Bryan Kitchen |
| | | President and Chief Executive Officer |
| | | (principal executive officer) |
| | | |
Date: | August 4, 2026 | By: | /s/ Ryan Kavalauskas |
| | | Ryan Kavalauskas |
| | | Chief Financial Officer |
| | | (principal financial and accounting officer) |